Ultrasound catheter

Information

  • Patent Grant
  • 11740138
  • Patent Number
    11,740,138
  • Date Filed
    Tuesday, December 3, 2019
    4 years ago
  • Date Issued
    Tuesday, August 29, 2023
    8 months ago
Abstract
A first tubular body having a first longitudinal axis extending centrally through the tubular body includes at least one delivery port extending through a wall of the first tubular body. A second tubular body having a second longitudinal axis extends through the second tubular body, the first and second longitudinal axes being displaced from each other such that an asymmetrical longitudinally extending gap is formed between an outer surface of the second tubular body and an interior surface of the first tubular body. A temperature sensor forming a thermocouple extending longitudinally within the gap between the first tubular body and the second tubular body. An inner core is positioned within the second tubular body. The inner core includes least one ultrasound element.
Description
FIELD

The present disclosure relates generally to an ultrasonic catheter and more specifically to an ultrasonic catheter configured to deliver ultrasonic energy and a therapeutic compound to a treatment site.


BACKGROUND

Several medical applications use ultrasonic energy. For example, U.S. Pat. Nos. 4,821,740, 4,953,565 and 5,007,438 disclose the use of ultrasonic energy to enhance the effect of various therapeutic compounds. An ultrasonic catheter can be used to deliver ultrasonic energy and a therapeutic compound to a treatment site within a patient's body. Such an ultrasonic catheter typically includes an ultrasound assembly configured to generate ultrasonic energy and a fluid delivery lumen for delivering the therapeutic compound to the treatment site.


As taught in U.S. Pat. No. 6,001,069, ultrasonic catheters can be used to treat human blood vessels that have become partially or completely occluded by plaque, thrombi, emboli or other substances that reduce the blood carrying capacity of the vessel. To remove or reduce the occlusion, the ultrasonic catheter is used to deliver solutions containing therapeutic compounds directly to the occlusion site. Ultrasonic energy generated by the ultrasound assembly enhances the effect of the therapeutic compounds. Such a device can be used in the treatment of diseases such as peripheral arterial occlusion, deep vein thrombosis or acute ischemic stroke. In such applications, the ultrasonic energy enhances treatment of the occlusion with therapeutic compounds such as urokinase, tissue plasminogen activator (“tPA”), recombinant tissue plasminogen activator (“rtPA”) and the like. Further information on enhancing the effect of a therapeutic compound using ultrasonic energy is provided in U.S. Pat. Nos. 5,318,014, 5,362,309, 5,474,531, 5,628,728, 6,001,069, 6,210,356 and 7,341,569.


Another use for ultrasonic catheters is in the treatment of pulmonary embolisms. Pulmonary embolisms (“PE”) are caused when a large blood clot obstructs the major blood vessels leading from the heart to the lungs. The victim's heart can be suddenly overwhelmed with the task of pushing blood past this obstruction. About 5% of PEs are classified as massive and can result in rapid heart failure, shock and death without immediate therapy. Such massive PEs have traditionally been treated by a large dose of clot-dissolving drug (i.e., a thrombolytic). However, such treatment can result in unintended bleeding and even fatalities. Up to 40% of PEs are less critical obstructions, often called sub-massive PE. Current treatment protocols include treatment with anti-coagulant medication. Such treatments do not remove the clot but simply prevent the clot from growing larger. Recent studies suggest that failure to remove these sub-massive clots may have long-term adverse consequences including recurrent PE, chronic pulmonary hypertension and death.


SUMMARY

In some embodiments, disclosed is an ultrasound catheter that includes a first tubular body having a first longitudinal axis extending centrally through the tubular body, the first tubular body including at least one delivery port extending through a wall of the first tubular body. In some embodiments, the ultrasound catheter includes a second tubular body having a second longitudinal axis extending centrally through the second tubular body, the first and second longitudinal axes being displaced from each other such that an asymmetrical longitudinally extending gap is formed between an outer surface of the second tubular body and an interior surface of the first tubular body. In some embodiments, the ultrasound catheter includes a temperature sensor forming a thermocouple extending longitudinally within the gap between the first tubular body and the second tubular body. In some embodiments, the disclosure includes an inner core positioned within the second tubular body, the inner core comprising at least one ultrasound element. In certain embodiments, the temperature sensor comprises a flexible circuit. In certain embodiments, the temperature sensor comprises a plurality of filament pairs wherein each of the filaments is insulated; and a plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.


In some embodiments, disclosed is a method of manufacturing a catheter. In some embodiments, the method includes inserting an inner tubular body into an outer tubular body. In some embodiments, the method includes placing a temperature sensor between the outer and inner tubular body, wherein the temperature sensor is adjacent to an outer surface of the inner tubular body such that the inner tubular body does not extend along the same longitudinal axis a the outer tubular body. In certain embodiments, the temperature sensor comprises a flexible circuit. In certain embodiments, the temperature sensor comprises a plurality of filament pairs wherein each of the filaments is insulated; and a plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.


In some embodiments, disclosed is an ultrasound catheter including an elongate inner tubular body. In some embodiments, the ultrasound catheter includes an elongate outer tubular wherein the elongate inner tubular body is positioned within the elongate outer tubular body to form an asymmetrical gap between an outer surface of the inner tubular body and an interior surface of the elongate outer tubular body to form a fluid delivery lumen. In some embodiments, the ultrasound catheter includes a temperature sensor extending along the outer surface of the inner tubular body within the gap. In some embodiments, the ultrasound catheter includes an inner core positioned within the inner tubular body and comprising at least one ultrasound element. In certain embodiments, the temperature sensor comprises a flexible circuit. In certain embodiments, the temperature sensor comprises a plurality of filament pairs wherein each of the filaments is insulated; and a plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.


In some embodiments, disclosed is a method of manufacturing a catheter including inserting an inner tubular body into an outer tubular body. In some embodiments, the method of manufacturing includes placing a temperature sensor between the outer and inner tubular body, wherein the temperature sensor is adjacent to an outer surface of the inner tubular body such that the inner tubular body does not extend along the same longitudinal axis a the outer tubular body. In certain embodiments, the temperature sensor comprises a flexible circuit. In certain embodiments, the temperature sensor comprises a plurality of filament pairs wherein each of the filaments is insulated; and a plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.


In some embodiments, disclosed is an ultrasound catheter including an elongate inner tubular body. In some embodiments, the ultrasound catheter includes an elongate outer tubular wherein the elongate inner tubular body is positioned within the elongate outer tubular body to form an asymmetrical gap between an outer surface of the inner tubular body and an interior surface of the elongate outer tubular body to form a fluid delivery lumen. In some embodiments, the ultrasound catheter includes a temperature sensor extending along the outer surface of the inner tubular body within the gap. In some embodiments, the ultrasound catheter includes an inner core positioned within the inner tubular body and comprising at least one ultrasound element.


In some embodiments, disclosed is a flexible circuit for a catheter. In some embodiments, the flexible circuit includes a plurality of traces formed on the flexible circuit separated by insulating material. In some embodiments, the plurality of traces includes at least two traces of a first material connected to a single trace of second dissimilar material at different points along a length of the flexible circuit. In some embodiments, a temperature sensor for a catheter comprises a plurality of filament pairs wherein each of the filaments is insulated; and a plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.


For purposes of summarizing the invention and the advantages achieved over the prior art, certain objects and advantages of the invention have been described in this application. It is to be understood that not necessarily all such objects or advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objects or advantages as may be taught or suggested herein.


All of these embodiments are intended to be within the scope of the invention herein disclosed. These and other embodiments of the present invention will become readily apparent to those skilled in the art from the following detailed description of the embodiments having reference to the attached figures, the invention not being limited to any particular embodiment(s) disclosed.





BRIEF DESCRIPTION OF THE DRAWINGS

Exemplary embodiments of the vascular occlusion treatment system are illustrated in the accompanying drawings, which are for illustrative purposes only. The drawings comprise the following figures, in which like numerals indicate like parts.



FIG. 1A is a schematic illustration of an ultrasonic catheter configured for insertion into large vessels of the human body.



FIG. 1B is a cross-sectional view of the ultrasonic catheter of FIG. 1A.



FIG. 1C is an enlarged cross-sectional view of a hub portion of the ultrasonic catheter of FIG. 1A.



FIG. 1D is a side view of the hub portion ultrasonic catheter of FIG. 1A.



FIG. 1E is an exploded illustration the hub portion of the ultrasonic catheter of FIG. 1A.



FIG. 1F is an enlarged cross-sectional side view of a modified hub portion of the ultrasonic catheter of FIG. 1A.



FIG. 1G is a side view of an embodiment of the hub portion of the ultrasonic catheter configured for insertion into the human body.



FIG. 1H is a side view of the embodiment of the hub portion of the ultrasonic catheter of FIG. 1G with attached fluid tubes configured for insertion into the human body.



FIG. 1I is an enlarged cross-sectional view of the hub portion of the ultrasonic catheter of FIG. 1H along section A-A



FIG. 1J is an enlarged cross-sectional view of the hub portion of FIG. 1H along section B-B.



FIG. 1K is a side view of the exterior tubular body of the hub portion of FIG. 1G.



FIG. 1L is a front view of another embodiment of the hub portion of the ultrasonic catheter configured for insertion into the human body.



FIG. 1M is a cross-sectional view of the hub portion of the ultrasonic catheter of FIG. 1L.



FIG. 1N is an enlarged cross-sectional view of the hub portion of the ultrasonic catheter of FIG. 1L along section B-B.



FIG. 1O is an enlarged cross-sectional view of the hub portion of the ultrasonic catheter of FIG. 1L along section C-C.



FIG. 2 is a cross-sectional view of the ultrasonic catheter taken along line 2-2 of FIG. 1C or anywhere along the length of the exterior tubular body of FIG. 1K.



FIG. 2A is a cross-sectional view of another embodiment of the ultrasonic catheter taken along line 2-2 of FIG. 1C or anywhere along the length of the exterior tubular body of FIG. 1K.



FIG. 2B is a top cross-sectional view of an embodiment of a flexible circuit (“flexcircuit”) that can be configured to form a thermocouple to serve as a temperature sensor in the ultrasonic catheter illustrated in FIGS. 1A-1O and FIGS. 2-2A.



FIG. 2C is a side cross-sectional view of the embodiment of the flexcircuit illustrated in FIG. 2B.



FIG. 2D is a side view of an embodiment of a temperature sensor composed of a plurality of insulated wires configured to form a plurality of thermocouples.



FIG. 2E is a top view of an embodiment of the temperature sensor of FIG. 2D.



FIG. 2F is an enlarged top view of a thermocouple junction of the temperature sensor of FIG. 2D.



FIG. 2G is a side view of another embodiment of a temperature sensor composed of a plurality of insulated wires configured to form a plurality of thermocouples.



FIG. 2H is a top view of another embodiment of a temperature sensor of FIG. 2G.



FIG. 2I is an enlarged top view of a thermocouple junction of the temperature sensor of FIG. 2G.



FIG. 3 is a schematic illustration of an elongate inner core configured to be positioned within the central lumen of the catheter illustrated in FIG. 2.



FIG. 4 is a cross-sectional view of the elongate inner core of FIG. 3 taken along line 4-4.



FIG. 5 is a schematic wiring diagram illustrating an exemplary technique for electrically connecting five groups of ultrasound radiating members to form an ultrasound assembly.



FIG. 6 is a schematic wiring diagram illustrating an exemplary technique for electrically connecting one of the groups of FIG. 5.



FIG. 7A is a schematic illustration of the ultrasound assembly of FIG. 5 housed within the inner core of FIG. 4.



FIG. 7B is a cross-sectional view of the ultrasound assembly of FIG. 7A taken along line 7B-7B.



FIG. 7C is a cross-sectional view of the ultrasound assembly of FIG. 7A taken along line 7C-7C.



FIG. 7D is a side view of an ultrasound assembly center wire twisted into a helical configuration.



FIG. 8 illustrates the energy delivery section of the inner core of FIG. 4 positioned within the energy delivery section of the tubular body of FIG. 2.



FIG. 9 illustrates a wiring diagram for connecting a plurality of temperature sensors with a common wire.



FIG. 10 is a block diagram of a feedback control system for use with an ultrasonic catheter.



FIG. 11A is a side view of a treatment site.



FIG. 11B is a side view of the distal end of an ultrasonic catheter positioned at the treatment site of FIG. 11A.



FIG. 11C is a cross-sectional schematic view of the distal end of the ultrasonic catheter of FIG. 11B positioned at the treatment site before a treatment.



FIG. 11D is a cross-sectional schematic view of the distal end of the ultrasonic catheter of FIG. 11C, wherein an inner core has been inserted into the tubular body to perform a treatment.



FIG. 12A is a horizontal cross-section showing a top view of another embodiment of a flexcircuit, with protective second coverlay 310 removed, that can be configured to form a thermocouple to serve as a temperature sensor in the ultrasonic catheter illustrated in FIGS. 1A-E.



FIG. 12B is a vertical cross-sectional view of the embodiment of the flexcircuit illustrated in FIG. 12A at a more proximal point.



FIG. 13 illustrates a schematic of a method of manufacturing a catheter comprising a flexcircuit.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As described above, it is desired to provide an ultrasonic catheter also referred to herein as “ultrasound catheter(s)” having various features and advantages. Examples of such features and advantages include the ability to apply ultrasonic energy to a treatment site. In other embodiments, the catheter has the ability to deliver a therapeutic compound to the treatment site. Embodiments of an ultrasonic catheter having certain of these features and advantages are described herein. Methods of using such an ultrasonic catheter are also described herein.


The ultrasonic catheters also referred to herein as “ultrasound catheter(s)” described herein can be used to enhance the therapeutic effects of therapeutic compounds at a treatment site within a patient's body. As used herein, the term “therapeutic compound” refers broadly, without limitation, to a drug, medicament, dissolution compound, genetic material, anti-cancer drug, or any other substance capable of effecting physiological functions. Additionally, any mixture comprising any such substances is encompassed within this definition of “therapeutic compound”, as well as any substance falling within the ordinary meaning of these terms. The enhancement of the effects of therapeutic compounds using ultrasonic energy is described in U.S. Pat. Nos. 5,318,014, 5,362,309, 5,474,531, 5,628,728, 6,001,069 and 6,210,356, the entire disclosures of which are hereby incorporated by herein by reference. Specifically, for applications that treat human blood vessels that have become partially or completely occluded by plaque, thrombi, emboli or other substances that reduce the blood carrying capacity of a vessel, suitable therapeutic compounds include, but are not limited to, an aqueous solution containing Heparin, Uronkinase, Streptokinase, TPA and BB-10153 (manufactured by British Biotech, Oxford, UK).


Certain features and aspects of the ultrasonic catheters disclosed herein may also find utility in applications where the ultrasonic energy itself provides a therapeutic effect. Examples of such therapeutic effects include preventing or reducing stenosis and/or restenosis; tissue ablation, abrasion or disruption; promoting temporary or permanent physiological changes in intracellular or intercellular structures; and rupturing micro-balloons or micro-bubbles for therapeutic compound delivery. Further information about such methods can be found in U.S. Pat. Nos. 5,261,291 and 5,431,663, the entire disclosures of which are hereby incorporated by herein by reference.


The ultrasonic catheters described herein can be configured for applying ultrasonic energy over a substantial length of a body lumen, such as, for example, the larger vessels located in the leg. In other embodiments, the catheter can be configured for treatment of pulmonary embolisms, (“PE”), which can be caused when a large blood clot obstructs the major blood vessels leading from the heart to the lungs. However, it should be appreciated that certain features and aspects of the present disclosure may be applied to catheters configured to be inserted into other vessels or cavities such as the small cerebral vessels, in solid tissues, in duct systems and in body cavities. Additional embodiments that may be combined with certain features and aspects of the embodiments described herein are described in U.S. Patent Publication US2004/0019318, entitled “Ultrasound Assembly For Use With A Catheter” and filed Nov. 7, 2002, the entire disclosure of which is hereby incorporated herein by reference.



FIG. 1A schematically illustrates an ultrasonic catheter 10 configured for use in the large vessels of a patient's anatomy. For example, the ultrasonic catheter 10 illustrated in FIG. 1A can be used to treat long segment peripheral arterial occlusions, such as those in the vascular system of the leg. In other examples, the ultrasonic catheter 10 illustrated in FIG. 1A can be used for treatment of a pulmonary embolism as described, for example, in U.S. Patent Publication US2012/0289889 (filed May 10, 2012), which is hereby incorporated by reference herein in its entirety. As will be explained in detail below, in some embodiments, the catheter is configured to be introduced into the patient's the major blood vessels leading from the heart to the lungs (e.g., the pulmonary artery). In one embodiment of use, femoral venous access may be used to place the catheter 10 into such vessels. In such embodiments, the catheter 10 can be advanced through femoral access site, through the heart and into the pulmonary artery. The dimensions of the catheter 10 are adjusted based on the particular application for which the catheter 10 is to be used.


As illustrated in FIG. 1A, the ultrasonic catheter 10 can include a multi-component, elongate flexible exterior tubular body 12 having a proximal region 14 and a distal region 15. The exterior tubular body 12 can include a flexible energy delivery section 18 located in the distal region 15 of the catheter 10. The exterior tubular body 12 and other components of the catheter 10 can be manufactured in accordance with any of a variety of techniques well known in the catheter manufacturing field. Suitable materials and dimensions can be readily selected based on the natural and anatomical dimensions of the treatment site and on the desired percutaneous access site.


For example, in some embodiments, the proximal region 14 of the exterior tubular body 12 can comprise a material that has sufficient flexibility, kink resistance, rigidity and structural support to push the energy delivery section 18 through the patient's vasculature to a treatment site. Examples of such materials include, but are not limited to, extruded polytetrafluoroethylene (“PTFE”), polyethylenes (“PE”), polyamides and other similar materials. In certain embodiments, the proximal region 14 of the exterior tubular body 12 is reinforced by braiding, mesh or other constructions to provide increased kink resistance and pushability. For example, nickel titanium or stainless steel wires can be placed along or incorporated into the exterior tubular body 12 to reduce kinking.


In some embodiments configured for treating thrombus in the arteries of the leg, the exterior tubular body 12 has an outside diameter between about 0.060 inches and about 0.075 inches (between about 0.15 cm and about 0.19 cm). In another embodiment, the exterior tubular body 12 has an outside diameter of about 0.071 inches (about 0.18 cm). In certain embodiments, the exterior tubular body 12 has an axial length of approximately 106 to 135 centimeters, although other lengths may by appropriate for other applications.


The energy delivery section 18 of the exterior tubular body 12 can include a material that is thinner than the material comprising the proximal region 14 of the exterior tubular body 12 or a material that has a greater acoustic transparency. Thinner materials generally have greater acoustic transparency than thicker materials. Suitable materials for the energy delivery section 18 can include, but are not limited to, high or low density polyethylenes, urethanes, nylons, and the like. In certain modified embodiments, the energy delivery section 18 may be formed from the same material or a material of the same thickness as the proximal region 14.


In certain embodiments, the exterior tubular body 12 can be divided into three sections of varying stiffness. In some embodiments, the first section, can include the proximal region 14, which can have a relatively higher stiffness. The second section, which can be located in an intermediate region between the proximal region 14 and the distal region 15 of the exterior tubular body 12, can have a relatively lower stiffness. This configuration further facilitates movement and placement of the catheter 10. The third section, which can include the energy delivery section 18, can be generally lower in stiffness than the second section in spite of the presence of the ultrasound radiating members 40.


To provide access to the interior of the exterior tubular body 12, a plurality of inlets can be fluidly connected to the proximal region 14 of catheter 10. In some examples, the proximal region 14 of the catheter 10 can include a cooling inlet port 46, a drug inlet port 32, and/or a proximal access port 31. In some embodiments, to provide an electrical connection to the energy delivery section 18, the catheter 10 can further include a cable 45 that can include a connector 101 to the control system 100 (shown in FIG. 10). In some variants, the cable 45 can be connected to the catheter 10 at the proximal region 14 through the proximal access port 31. In some examples, the catheter 10 can further include a backend hub 33 that helps to secure the various inlet ports at the proximal region 14 of the catheter 10.



FIGS. 1B-E illustrate various views of the ultrasound catheter of FIG. 1A. FIGS. 1B-1C illustrate cross-sectional views of the hub 33 and FIG. 1D-D illustrates a side view of the hub 33. FIG. 1E illustrates an exploded view of the hub 33.



FIG. 2 illustrates a cross section of the exterior tubular body 12 taken along line 2-2 in FIG. 1B. As shown in FIG. 2, in the illustrated embodiment the catheter 10 may be formed of two lumens—fluid delivery lumen 30 and central lumen 51, which can be formed from an interior wall of an exterior tubular body 12 and an interior wall of an interior tubular body 13, respectively. In some examples, the interior tubular body 13 can be located within the exterior tubular body 12 such that a gap 52 is formed between an interior wall of the exterior tubular body 12 and an exterior wall of the interior tubular body 13 such that the fluid delivery lumen 30 extends coaxially about the interior tubular body. In the embodiment shown in FIG. 2, the exterior tubular body 12 has a first longitudinal axis L1 extending centrally through the exterior tubular body 12, and the interior tubular body 13 has a second longitudinal axis L2 extending centrally through the interior tubular body 13. The first and second longitudinal axes L1, L2 are displaced from each other such that an asymmetrical gap 52 is formed between an outer surface of the interior tubular body 13 and an interior surface of the exterior tubular body 12. In other embodiments, more or fewer fluid delivery lumens can be formed by a plurality of tubular bodies located within the exterior tubular body 12 and/or by the addition of dividers and/or channels.


With continued reference to FIG. 2, in some examples, the exterior tubular body 12 can further include a temperature sensor 20 that can be positioned within the fluid delivery lumen 30 between the outside surface of the of the interior tubular body 13 and the interior surface of the exterior tubular body 12. As will be described in more detail below, the temperature sensor 20 shown in FIGS. 2 and 8 can be a flexible circuit or “flexcircuit” 220 as shown in FIGS. 2A and 2B or flexcircuit 320 as shown in FIGS. 12A and 12B. In some embodiments the flexible circuit is configured to form a hermocouple. In certain embodiments, the temperature sensor 20 shown in FIGS. 2 and 8 can be a ribbon thermocouple 500 as shown in FIGS. 2D-2F or a ribbon thermocouple 600 as shown in FIGS. 2G-2I. As described below, there are potential advantages to embodiments that utilize a flexible circuit 220, 320 and/or thermocouple ribbon 500, 600 as described herein. However, in certain embodiments of the ultrasonic catheter 10, the temperature sensor 20 can take other configurations or forms. In some embodiments, the temperature sensor 20 is positioned on a side of the interior tubular body 13 such that the interior tubular body 13 is positioned asymmetrically within the exterior tubular body 12. In such an arrangement, an asymmetrical longitudinally extending gap 52 is formed between an outer surface of the interior tubular body (corresponding to the second tubular body) and an interior surface of the exterior tubular body (corresponding to the first tubular body); thus in the illustrated arrangement the gap 52 between the outer surface of the interior tubular body and the interior surface of the exterior tubular body can be an asymmetrical gap 52 (a crescent shape), which can have certain advantages as described below. It is therefore preferred that the flexible circuit or ribbon thermocouple is positioned in the widest portion of the asymmetrical gap 52, and optionally, adjacent the exterior surface of the interior tubular body. In an embodiment, the flexible circuit or ribbon thermocouple can be coupled to the outside surface of the interior tubular body 13 at one or more locations. In an embodiment, the flexible circuit or ribbon thermocouple can be coupled to the outside surface of the interior tubular body 13 at a distal end of the catheter 10. While not illustrated in FIGS. 2 and 8, in some embodiments, the flexible circuit or ribbon thermocouple can contact an interior surface of the exterior tubular body 12 (corresponding to the first tubular body) in addition to or, as an alternative, in some embodiments, to contacting the outer surface of the interior tubular body 13 (corresponding to the second tubular body). In certain embodiments, the flexible circuit 220 as shown in FIGS. 2A and 2B or flexcircuit 320 as shown in FIGS. 12A and 12B or be ribbon thermocouple 500 as shown in FIGS. 2D-2F or a ribbon thermocouple 600 as shown in FIGS. 2G-2I when positioned as shown in FIGS. 2 and 8, can bend and be curved as shown in FIGS. 2 and 8 to form a crescent shape corresponding to the outer surface of the interior tubular body 13 (corresponding to the second tubular body) and/or the interior surface of the exterior tubular body 12 (corresponding to the first tubular body).



FIG. 2A illustrates another embodiment of the cross section of an exterior tubular body 12. As shown in FIG. 2A, the exterior tubular body 12 can be disposed about the interior tubular body 13. An inner core 706 can be inserted within the interior tubular body 13 and positioned at a treatment site. As noted with regard to FIG. 2, the exterior tubular body 12 can also include a temperature sensor 20 which can be arranged in accordance with any of the embodiments described herein.


In some embodiments, the interior tubular body 13 can include an uneven exterior and/or interior surface that can, as will be discussed in more detail, additional cooling within the device. In some embodiments, the interior tubular body 13 can have a non-circular cross-section. In some embodiments, the interior tubular body 13 can include a plurality of indentations 786 and/or protrusions 787 such that the interior tubular body 13 does not have a circular interior surface and/or exterior surface. Because the diameter of the inner core 706 is less than the diameter of the interior tubular body, in an interior tubular body with a circular interior surface, the inner core 706 could be placed against the interior tubular body 13 such that there could be a relatively large portion with no or minimal gap between the exterior surface of the inner core 706 and the interior surface of the interior tubular body 13 and/or a relatively large portion with no or minimal gap between the exterior of the interior tubular body 13 and the interior of the exterior tubular body 12. This can potentially cause uneven over-heating of the inner core 706. The indentations 786 can therefore ensure that cooling fluid will have room to flow past the inner core 706 and contact more external surfaces of the inner core 706. In a similar manner, drug flowing between the interior tubular body 13 and the exterior tubular body 12 can be more uniformly distributed between the two tubular components as a result of an uneven surface about the exterior of the interior tubular body 13. In some embodiments, the exterior of the interior tubular body 13 can include indentations 788 and/or protrusions 789. In some embodiments, the plurality of indentations 788 and/or protrusions 789 can ensure that the inner core 706 does not cause overheating within the exterior tubular body 12. In some examples, as the indentations 786, 788 and/or protrusions 787, 789 can be of any shape or size, this can reduce manufacturing costs as any imperfection on the inner and/or outer surface of the tubular body 13 would provide additional cooling benefits to the inserted inner core 706. The indentations 786, 788 and/or protrusions 787, 789 can extend longitudinally along the length of the interior tubular body 13. In certain embodiments, the indentations 786, 788 and/or protrusions 787, 789 can extend longitudinally along at least 50% of the length of the interior tubular body 13 and along at least 75% of the length of the interior tubular body 13 and in certain embodiments along at least 90% of the length of the interior tubular body 13. The embodiment of the interior tubular body 13 with indentations 786, 788 and/or protrusions 787, 789 can be used in combination with the temperature sensors described herein and/or used independently to promote uniform cooling.


Temperature Sensor


Turning first to the flexcircuits illustrated in FIGS. 2B-C and 12A-12B, as described above, the temperature sensor 20 can comprise a flexible circuit (“flexcircuit”) that is configured to form one or more thermocouples. The flexcircuit can be used to measure the temperature at different points along the length of the catheter 10, and so it is preferred that the flexible circuit extends along the length of the central first tubular body.



FIG. 2B illustrates a top view of one embodiment of the flexcircuit 220 and FIG. 2C is a cross-sectional view of the flexcircuit 220. FIGS. 12A-12B illustrate two views of another embodiment of a flexcircuit 320. With reference to FIGS. 2B and 2C, on one embodiment, the flexcircuit 220 is composed of a plurality of traces. In one embodiment, the flexcircuit 220 includes a first trace 207 that runs the entire length of the flexcircuit 220. The first trace is preferably constantan. Constantan is a copper-nickel alloy that has a constant resistivity over a wide range of temperatures. The first trace 207 can therefore provide good temperature sensitivity along its length. While a constantan trace is preferred, modified embodiments can include a trace of a different material.


To form the thermocouple, the flexcircuit 220 includes a plurality of second traces formed of a material different than the first trace 207. Each individual trace of this plurality of second traces extends from the proximal end 230 to a different point along the length of the flexcircuit 220. In some examples, the individual traces of this plurality of second traces are made of copper overlaid on the flexcircuit 220. In the illustrated embodiment, the first trace is Constantan and the plurality of second traces are formed from copper. In other embodiments, the first and second materials can be a different combination of materials. For example, the first material can be Alumel (consisting of approximately 95% nickel, 2% manganese, 2% aluminum and 1% silicon) and the second material can be Chromel (90% nickel and 10% chromium) as can be found in a Type K thermocouple or other combinations of dissimilar materials. In one example, the flexcircuit 220 can include a trace 201 that extends from the proximal end 230 of the flexcircuit 220 to a joint 211 at the distal end 240 of the flexcircuit 220. Similarly, the flexcircuit 220 can include one or more of any of the following traces: trace 201 that extends from the proximal end 230 to a joint 211 close to a distal end of the flexcircuit 220, trace 202 that extends from the proximal end 230 to a joint 212, trace 203 that extends from the proximal end 230 to a joint 213, trace 204 that extends from the proximal end 230 to a joint 214, trace 205 that extends from the proximal end 230 to a joint 215, and trace 206 that extends from the proximal end 230 to a joint 216 closer to a proximal end of the flexcircuit 220. In some examples, the plurality of joints (e.g. joint 211, joint 212, joint 213, joint 214, joint 215, and joint 216) allows the temperature to be taken along several points along the length of the flexcircuit 220. In some variants, this can help to measure the temperature of the ultrasonic catheter along the entire length of the device or a portion of the device (e.g., a portion of the device that includes the ultrasound elements described below). In modified embodiments, the traces 201-206 and joints 211-216 can be arranged in different orders or configurations.


When temperature differential is experienced by the different conductors (e.g., between one of the traces 201-206 and the first trace 207), it produces a voltage when the temperature of one of the spots differs from the reference temperature at other parts of the circuit. In this manner, temperatures along the flexcircuit 220 can be measured by measuring the voltages between one of the traces 201-206 and the first trace 207. The illustrated preferred embodiment of FIG. 2B includes a single first trace of Constantan and six (6) traces of copper, although in other embodiments other dissimilar material combinations such as Alumel and Chromel may be used together, respectively. In modified embodiments more or fewer traces and/or traces formed of different materials each dissimilar from the first trace may be used. An advantage of the illustrated embodiment is that a single first trace can be used to measure the temperature at multiple locations along the length of the flexcircuit 220, which can reduce the overall size of the flexcircuit as compared to a circuit with multiple first traces; in the preferred embodiment, a single Constantan trace is used as the first trace, which can reduce the overall size of the flexcircuit as compared to a circuit with multiple Constantan first traces. In modified embodiments, the flexcircuit can include multiple first traces that are each individually associated with the individual traces of the plurality of second traces of dissimilar materials.


In some embodiments, the flexcircuit 220 can be of variable length and can be configured to run the entire length or a portion of the catheter 10. Similarly, to measure temperature along the length of the flexcircuit 220, the distance between the joints 211-216 can be varied for the catheter 10. In the one embodiment, the flexcircuit 220 can have a length l1 from proximal end 230 to distal end 240 of about 115 cm. In some embodiments, the distance between each of the joints 211-216 (e.g. length l2, length l3, length l4, length l5, length l6) can be approximately 10 cm. In additional embodiments, the distance between each of the joints 211-216 can be between 1.0 cm and 50.0 cm depending upon the number of joints and the desired overall length of the flexcircuit 220. The distance between the joints 211-216 need not be uniform in certain embodiments. As mentioned above, in one arrangement, the joints are positioned generally along the length of the catheter in which the ultrasound elements are positioned such that the temperature of the catheter around the ultrasound elements can be monitored. Accordingly, in the illustrated embodiment the joints 211, 212, 213, 214, 215, 216 are positioned in the energy delivery section 18 of the exterior tubular body 12.



FIG. 2C illustrates a side cross-sectional view of the flexcircuit 220. As described previously, the flexcircuit 220 can be formed by a plurality of layered traces. In one example, the flexcircuit 220 includes the first trace 207 formed on a bottom middle layer 224. In some variants, the first trace 207 can be 0.001 inch (0.003 cm) thick. The flexcircuit 220 can include three traces 202, 204, 206 and 201, 203, 205 formed on a top middle layer 225, respectively, that can be formed from a different material than the first trace 207 and arranged as described above. Each of the second or copper traces can be separated from each other by adhesive 231 which can fill in the gaps between layers of the flexcircuit and traces In the illustrated embodiments the flexcircuit 220 can include a plurality of insulating layers between each of the layers containing the traces. As discussed above, aside from where a joint between two of the conductive layers are formed (e.g. joint 211, joint 212, joint 213, joint 214, joint 215, and joint 216), the plurality of insulating layers covers the length of the trace to insulate each of the traces from each other. The flexible circuit therefore comprises a plurality of joints 211, 212, 213, 214, 215 and 216 between the dissimilar materials of the first trace 207 and each of the plurality of second traces 201, 202, 203, 204, 205 and 206. As illustrated in FIG. 12B, the flexcircuit 220 can include a bottom coverlay 221, the bottom middle layer 224, top middle layer 225, and a top coverlay 227 that forms an insulating layer between each of the trace layers. The flexcircuit 220 of the illustrated embodiment also includes additional top insulating layer 218 and bottom insulating layer 217 which can cover electrically conducting vias which form the joints 211-216 that connect corresponding traces. In the preferred embodiment, each of these insulating layers can be formed of polyimide. In an embodiment, the top insulating layer 218 and bottom insulating layer 217 can extend along the entire length of the flexcircuit 220. In another embodiment, the top insulating layer 218 and bottom insulating layer 217 can cover portions of the flexcircuit 220 around the joints 211-216. In one embodiment, the joints 211-216 are formed by forming an electrically conducting via through the flexcircuit 220 to electrically connect the respective first trace 207 and second traces 201-206. The via can then be covered with the top insulating layer 218 and bottom insulating layer 217. As shown in FIG. 2C, gaps between the respective layers and traces can be filled in with an adhesive 231.



FIGS. 12A-12B illustrate another embodiment of a flexcircuit 320. FIG. 12A shows a vertical cross-sectional view of the flexcircuit 320 at a proximal point. As shown, the flexcircuit 320 can include a plurality of traces that are located on each of the top and bottom surfaces of the flexcircuit 320. As an example illustrated in FIG. 12B, the top surface can include a plurality of second traces 301, 302, and 303 whereas the bottom surface can include a plurality of second traces 304, 305, and 306, with a first trace 307 running laterally on a side, in this case the right side. The traces on the top and bottom surface of the flexcircuit 320 are separated by an insulator 308. In some examples, the bottom surface of the flexcircuit 320 can include a protective first coverlay 309 whereas the top surface of the flexcircuit 320 can include a protective second coverlay 310. The thickness of the flexcircuit 320 can be approximately 0.004 cm and the width of the flexcircuit 320 can be approximately 0.021 cm. In some embodiments, each of the traces of the flexcircuit 320 can be separated by a space of 0.003 cm.


The flexcircuit 320 can include a first material trace 307 that runs parallel to the length of the flexcircuit 320. In order to measure temperature at a specific point along the flexcircuit 320, each of the traces (e.g. trace 301, trace 302, trace 303, trace 304, trace 305, and trace 306) runs a varied distance along the flexcircuit 320. Traces (e.g. trace 301, trace 302, trace 303, trace 304, trace 305, and trace 306) can be made of a second material different from the first material. As with the embodiment of FIGS. 2A-2B, in one embodiment, the first material is Constantan and the second material is copper. In other embodiments, other dissimilar material combinations such as Alumel and Chromel can be used together. In some examples, where a temperature measurement is desired, one of the traces can make a right angle and form a node to contact the constantan trace 307.



FIG. 12A is a horizontal cross section illustrating a top view of a section of the flexcircuit 320 with protective second coverlay 310 removed. As illustrated, a temperature measurement can be obtained at node 312—a point along the flexcircuit 320. Each of the traces (e.g. trace 301, trace 302, trace 303, trace 304, trace 305, and trace 306) can run parallel along the length of the flexcircuit 320. At varying points, a node is formed where the trace turns to contact the first material trace 307. FIG. 12A shows a view taken at a more distal point than that shown in FIG. 12B, as at the segment of the flexcircuit 320 shown in FIG. 12A, the trace 303 has already formed a node to determine the temperature at a point further ahead proximally and therefore does not appear in this view. As well, trace 301 continues to run distally across the length of the segment shown in FIG. 12A and can therefore determine the temperature of the flexcircuit 320 distally further down along the length of the flexcircuit 320. The node 312 (and any of nodes 311, 313, 314, 315 and 316 (not shown)) can have a width of 0.011 cm and a height of 0.006 cm. Nodes 311, 312, 313, 314, 315 and 316 therefore constitute a plurality of joints between the dissimilar materials of the first material trace 307 and each of the plurality of second traces 301, 302, 303, 304, 305 and 306.


In certain embodiments, the temperature sensor 20 can be a ribbon thermocouple composed of a plurality of wires or that are coupled together. For example, FIGS. 2D-2F illustrate an embodiment of ribbon thermocouple 500. In some embodiments, the ribbon thermocouple 500 can be composed of a plurality of filaments and a plurality of thermocouple junctions. The plurality of filaments can be adhered together along the entire length of the ribbon thermocouple 500, from the proximal end 550 to the distal end 560. As will be discussed in more detail below, each of the plurality of filaments are adhered together except within 0.50 inches of the formed thermocouple junction.


As shown in FIG. 2E, in some embodiments, the ribbon thermocouple 500 can include filament 501, filament 502, filament 503, filament 504, filament 505, filament 506, filament 507, filament 508, filament 509, filament 510, filament 511, and filament 512. In some examples, each of the filaments is composed of a conductor 520 and an insulator 522. In some embodiments, the conductor 520 of each of the filaments is composed of a material such as copper or constantan. In some embodiments, the material of the conductor 520 of each of the filaments alternates. For example, filament 501, filament 503, filament 505, filament 507, filament 509, and filament 511 is composed of copper and filament 502, filament 504, filament 506, filament 508, filament 510, and filament 512 is composed of constantan. In some embodiments, the insulator 522 of each of the filaments is composed of polyesterimide.


In some examples, the ribbon thermocouple 500 can be configured to form a plurality of thermocouples along the length of the ribbon thermocouple 500 from the proximal end 550 to the distal end 560. In some embodiments, each of the thermocouples can be formed by stripping adjacent filaments of insulation and soldering the exposed conductor 520 together to form a thermocouple joint. As illustrated in FIGS. 2D-2E, thermocouple junction 530 can be formed by stripping filament 501 and filament 502 and soldering them together, thermocouple junction 531 can be formed by stripping filament 503 and filament 504 and soldering them together, thermocouple junction 532 can be formed by stripping filament 505 and filament 506 and soldering them together, thermocouple junction 533 can be formed by filament 507 and filament 508 and soldering them together, thermocouple junction 534 can be formed by filament 509 and filament 510 and soldering them together, and thermocouple junction 535 can be formed by filament 511 and filament 512 and soldering them together.


In some examples, the two filaments of the thermocouple junction are formed of different materials. In some embodiments, one of the two filaments of the thermocouple junction is formed of copper and one of the two filaments of the thermocouple junction is formed of constantan.


As shown in FIG. 2E, in some embodiments, the filaments are terminated at the formed thermocouple junction. FIG. 2F illustrates an enlarged view of the thermocouple junction 535 along section A-A of FIG. 2E. As discussed above, the distal end 560 of the pair of filaments has a stripped portion 570. In some embodiments, the stripped portion 570 of the pair of filaments is attached together with a solder 540. In some examples, the attachment of the two filaments is done by laser welding. In some examples, the insulation of the pair of filaments is laser stripped. In some embodiments, the solder is composed of about 95% to about 99% tin. In some examples, the thermocouple junction 535 includes a joint insulation 580. In some embodiments, the joint insulation 580 is composed of a polymer.



FIGS. 2G-2I illustrate another embodiment of a ribbon thermocouple 600 composed of a plurality of filaments and a plurality of thermocouple junctions. The plurality of filaments can be adhered together along the entire length of the ribbon thermocouple 600, from the proximal end 650 to the distal end 660. As will be discussed in more detail below, each of the plurality of filaments can be adhered together along the entire length of the ribbon thermocouple 600.


As shown in FIG. 2H, in some embodiments, the ribbon thermocouple 600 can include filament 601, filament 602, filament 603, filament 604, filament 605, filament 606, filament 607, filament 608, filament 609, filament 610, filament 611, and filament 612. In some examples, each of the filaments is composed of a conductor 620 and an insulator 622. In some embodiments, the conductor 620 of each of the filaments is composed of a material such as copper or constantan. In some embodiments, the conductor 620 of each of the filaments alternates. For example, filament 601, filament 603, filament 605, filament 607, filament 609, and filament 611 is composed of copper and filament 602, filament 604, filament 606, filament 608, filament 610, and filament 612 is composed of constantan.


In some examples, the ribbon thermocouple 600 can be configured to form a plurality of thermocouples along the length of the temperature sensor 600 from the proximal end 650 to the distal end 660. In some embodiments, each of the thermocouples can be formed by stripping adjacent filaments of insulation and soldering the exposed conductor 520 together to form a thermocouple joint. As illustrated in FIGS. 2G-2I, thermocouple junction 630 can be formed by stripping filament 601 and filament 602 and soldering them together, thermocouple junction 631 can be formed by stripping filament 603 and filament 604 and soldering them together, thermocouple junction 632 can be formed by stripping filament 605 and filament 606 and soldering them together, thermocouple junction 633 can be formed by filament 607 and filament 608 and soldering them together, thermocouple junction 634 can be formed by filament 609 and filament 610 and soldering them together, and thermocouple junction 635 can be formed by filament 611 and filament 612 and soldering them together.


In some examples, the two filaments of the thermocouple junction are formed of different materials. In some embodiments, one of the two filaments of the thermocouple junction is formed of copper and one of the two filaments of the thermocouple junction is formed of constantan.


As shown in FIG. 2H, each of the filaments extends from the proximal end 650 to the distal end 660, with the thermocouple junctions formed on a portion of the filaments. FIG. 2I illustrates an enlarged view of the thermocouple junction 635 along section A-A of FIG. 2H. As discussed above, a portion of the pair of filaments has a stripped portion 670 to form a window in the insulator 622 along the pair of filaments. In some examples, the insulation of the pair of filaments is laser stripped. In some embodiments, the stripped portion 670 of the pair of filaments is attached together with a solder 640. In some examples, the attachment of the two filaments is done by laser welding. In some embodiments, the solder is composed of about 95% to about 99% tin. In some embodiments, the thermocouple junction 635 includes a joint insulation 680. In some examples, the joint insulation 680 is composed of a polymer.


The illustrated embodiments of FIGS. 2-2I and 12A-12B have several advantages. For example, prior art ultrasound catheters have included a plurality of separate thermocouple wires extending along the length of the catheter in order to measure the temperature of the catheter at several locations along the energy delivery section of the catheter. By replacing the plurality of wires with a single flexible circuit or ribbon thermocouple with a plurality of nodes along the length of the flexcircuit or ribbon thermocouple, the complexity and costs associated with assembling the catheter can be reduced as only a single element (flex circuit or ribbon thermocouple) needs to be inserted between the catheter elements. In addition, as shown in FIGS. 2-2A, exterior tubular body 12 and the interior tubular body 13 can be configured into an asymmetrical arrangement so as to accommodate the flexcircuit or ribbon thermocouple. This asymmetrical arrangement can provide additional room for the flexcircuit or ribbon thermocouple and its plurality of traces or wires. However, surprisingly the asymmetrical shape of the asymmetrical gap 52 between the exterior tubular body 12 and the interior tubular body 13 does not adversely affect the delivery of drug through the catheter and to the treatment zone.


In some embodiments, the ribbon thermocouple design of FIGS. 2D-2I can include a gap between each of the pair of wires that are configured to form a thermocouple. In some examples, the distance between the conductors of each of the wires is closer together than the distance between each of the pair of wires that are configured to form a thermocouple. In some embodiments, this can help with the forming of the thermocouples. The distance between each of the pair of wires can aid in the removal of insulation material and the subsequent electrical connection of the exposed conductors. As discussed above, in some embodiments, the formation of an electrical connection of the exposed conductors can be through welding, soldering, or other electrical coupling method.


Ultrasound Catheters


Turning back to FIG. 1E, to provide access to the interior of the catheter 10, the proximal region 14 can include a distal hub 65 that can provide access to the asymmetrical gap 52 and a proximal hub 60 that can be configured to provide access to the central lumen 51. With reference to FIGS. 1B and 1E, a proximal end of the exterior tubular body 12 can extend through a nose cone 70 and can be coupled to the distal hub 65 through by a barbed fitting on the distal hub 65. In this manner, the distal hub 65 can provide access to asymmetrical gap 52 between the tubular body 12 and the internal tubular body 13 as shown in FIG. 2. Fluid lumen 30 includes a gap 52 between the exterior tubular body 12 and the internal tubular body 13. With reference to FIGS. 1B and 2, the fluid lumen inlet port 32 and the cable port 47 are in communication with this asymmetrical gap 52. That is to say, the fluid lumen inlet port 32 is a first fluid injection port in fluid communication with the gap 52. A cable 45 can extend through the cable port 47 and can be coupled the temperature sensor 20. The interior tubular body 13 can extend through the distal hub 65 and can be coupled to the proximal hub 60 such that the interior of the proximal hub 60 is in communication with the central lumen 51. As shown in FIG. 1B, the interior fluid port 46 is in communication with the interior of the proximal hub 60 such that fluid injected through the fluid port 46 will enter the central lumen 51. Thus, interior fluid port 46 is a fluid injection port in fluid communication with the interior of the interior tubular body 13. As illustrated, the proximal hub 60 can, in turn, be connected to a proximal end of the internal tubular body 13 by a barbed fitting on the proximal hub. While in the illustrated embodiment, barb fittings are used to connect the exterior tubular body 12 and the internal tubular body 13 to the distal hub 65 and proximal hub 60 respectively, in modified embodiments, other connection configurations can be such as such as flanged and threaded flared connections.


For example, FIG. 1F illustrates a cross-sectional view of another embodiment of the backend hub 33′. As discussed with regard to the backend hub 33 in FIGS. 1B & 1E, the backend hub 33′ can include a plurality of components that can provide access to the interior of the exterior tubular body 12. In some embodiments, the backend hub 33′ can be configured to retain a proximal hub 60′.


Unlike the hub described in FIGS. 1B & 1E which is composed of a distal hub 65 and a proximal hub 60, the proximal hub 60′ spans the entire length of the backend hub 33′ and provides a fluid connection to the interior of the catheter 10. The proximal end of the interior tubular body 13 is secured to the inside surface of the backend hub 33′ through a threaded flared fitting 71′.


The proximal hub 60′ also includes a plurality of inlets to provide fluid communication with the interior of the catheter 10. The proximal hub 60′ can have a proximal access port 31′. In some examples, the proximal hub 60′ can include a second barb inlet 75′ which can provide fluid communication to the gap 52 and a third barb inlet 63′ that can provide access to the central lumen 51. In the embodiment illustrated in FIG. 1F, the cable 45′ can be provided through an opening in the proximal hub 60′. As discussed above, the cable 45′ can provide an electrical connection for the temperature sensor 20.


The proximal hub 60′ can be secured to the nosecone 70′ through a plurality of components. As illustrated in FIG. 1F, the distal end of the proximal hub 60′ includes a plurality of threads 66a′ that is secured to the inside surface of a flared fitting 66′. The flared fitting 66′ can further include a plurality of barbed connectors that protrude from the surface of the nose cone 70 to secure the proximal hub 60′ and flanged fitting 66′ to the inside of the nosecone 70′.


With continued reference to FIGS. 1B and 1E, the distal hub 65 can include a first barb inlet 69 can be coupled to a connector 73 through which a cable 45 can extend. The temperature sensor 20 can be connected to the cable with one or both components extending partially through the first barb inlet 69 and connector 73. The distal hub 65 can also include a second barb inlet 75 which can be connected to the inlet port 32 to provide fluid communication to the gap 52. The proximal hub 60 can include a third barb inlet 63 and a proximal access port 31 that provides access to the central lumen 51. The third barb inlet 63 can be connected to the interior fluid port 46. In a modified embodiment, one or more of the first, second and third barb inlets 69, 75 and/or 63 can be replaced with flanged and/or flared fittings.


As discussed above, a plurality of components may be attached to the inlets of the distal hub 65 and proximal hub 60 to be in fluid communication with the interior of the exterior tubular body 12. As illustrated in FIGS. 1B-1E, a cable 45 can be attached to or extend through the first barb inlet 69 to form an electrical connection with the temperature sensor 20. In some embodiments the cable 45 is secured to the first barb inlet 69 through the use of connector 73 which can include an adhesive lining. In some embodiments, the cable 45 can include a connector 101 to the control system 100. Similarly, the fluid line 91 with fluid inlet port 32 can be attached to the second barb inlet 75 to provide fluid access to the asymmetrical gap 52. As well, in some embodiments, the cooling fluid line 92 with cooling fluid inlet port 46 can be attached to the barb inlet 63 to provide fluid access to the cooling fluid inlet port 46. The fluid inlet port 32 and cooling fluid inlet port 46 can be provided with luer fittings to facilitate connections to other components.


In order to secure the aforementioned components in the proximal region 14 of the catheter 10, the catheter 10 can include a housing structure to secure the fluid line 91 and cooling fluid line 92 to the inlets of the distal hub 65 and proximal hub 60. In some examples, as illustrated in FIG. 1E, the catheter 10 can include a backend hub 33 that has a first and second portion. The two parts of the backend hub 33 can be disposed about the proximal hub 60 and distal hub 65 so as to secure the distal hub 65 and proximal hub 60 in place. In some examples, the 65 and proximal hub 60 is further secured by the nosecone 70. In some embodiments, the nosecone 70 can be further retained by the backend hub 33 which secures the nosecone 70 at the distal end of the distal hub 65.


As noted above, in some embodiments, the arrangement of the exterior tubular body 12 and the interior tubular body 13 can be configured into an asymmetrical arrangement so as to accommodate the temperature sensor 20. As illustrated in FIG. 2, the central lumen 51 and temperature sensor 20 are located within the fluid delivery lumen 30. The cross-section of the exterior tubular body 12, as illustrated in FIG. 2, can be substantially constant along the length of the catheter 10. Thus, in such embodiments, substantially the same cross-section is present in both the proximal region 14 and the distal region 15 of the catheter 10, including the energy delivery section 18. In certain embodiments, the same or asymmetrically shaped cross-section is present along at least 50% of the length of the catheter, in other embodiments, at least 75% of the length of the catheter and in other embodiments at least 90% of the length of the catheter.


In some embodiments, the central lumen 51 has a minimum diameter greater than about 0.030 inches (greater than about 0.076 cm). In other embodiments, the central lumen 51 has a minimum diameter greater than about 0.037 inches (greater than about 0.094 cm), although other dimensions may be used in other applications. As described above, the central lumen 51 can extend through the length of the exterior tubular body 12. As illustrated in FIG. 1C, the central lumen 51 can have a distal exit port 29 and a proximal access port 31. As noted above, in some embodiments, the proximal access port 31 forms part of the backend hub 33, which is attached to the proximal region 14 of the catheter 10. In some examples, the backend hub 33 can further include cooling fluid inlet port 46 which is hydraulically connected to the central lumen 51. In some embodiments, the backend hub 33 can also include a fluid inlet port 32, which is in hydraulic connection with the asymmetrical gap 52 in the fluid delivery lumen 30, and which can be hydraulically coupled to a source of drug or therapeutic compound via a hub such as a Luer fitting. This embodiment of the disclosure therefore comprises a first fluid injection port (fluid inlet port 32) in fluid communication with the gap 52.


The central lumen 51 can be configured to receive an inner core 34 comprising a plurality of ultrasound radiating members extending along a length of the ultrasound catheter. FIG. 3 illustrates an embodiment of elongate inner core 34, which can be inserted into the central lumen 51. In some embodiments, the elongate inner core 34 can include a proximal region 36 and a distal region 38. A proximal hub 37 can be fitted on the inner core 34 at one end of the proximal region 36. As will be described below, in an arrangement, one or more ultrasound radiating members can be positioned within an inner core 34 located within the distal region 38. The ultrasound radiating members 40 can form an ultrasound assembly 42, which will be described in detail below. In one embodiment, when the inner core 34 can be positioned within the central lumen such that the ultrasound assembly 42 is positioned generally within the energy delivery section 18 of the catheter 10. As noted above, in one embodiment, the joints 212, 213, 214, 215, 216 of the flex circuit can be positioned adjacent the ultrasound assembly 42 and/or within the energy delivery section 18 of the catheter 10 and/or the thermocouple junctions of a the ribbon thermocouple can be positioned adjacent the ultrasound assembly 42 and/or within the energy delivery section 18 of the catheter.



FIGS. 1G-1J illustrate another embodiment of a back end hub 745, which can be used in the embodiments describe herein. As with the other embodiments, the hub 745 can be coupled to the, the exterior tubular body 12, the interior tubular body 13, and a plurality of inlets. In some examples, the ultrasonic catheter 700 can include a plurality of inlets. For example, the ultrasonic catheter 700 can include a first barb inlet 740, a second barb inlet 750, and a proximal access port 755.


In some embodiments, the hub 745 of the ultrasonic catheter 700 can be composed of a plurality of nested components that are sealed together. As illustrated in FIGS. 1G-1H, in some examples, the hub 745 can be composed of a cap 710 and a manifold body 730. A cross-section of each of the portions of the hub 745 is illustrated in greater detail in FIGS. 1I-1J. In some examples, the components of the hub 745 can be composed of a high density poly ethylene (“HDEV”). In some embodiments, the components of the hub 745 can be composed of a polycarbonate.


Turning first to FIG. 1J, illustrated is a cross-section along circle B-B of the cap 710 in FIG. 1H. In some embodiments, the cap 710 is disposed about a distal end of the distal end 736 of the manifold body 730. As shown, in some examples, the cap 710 has internal threads 312 that are disposed about the internal surface of the cap 710. The cap internal threads 712 are configured to engage with the external threads 734 disposed about the external surface of the distal end 736. As will be discussed in more detail below, in some embodiments, the manifold body 730 and the cap 710 have an interior lumen that secures the exterior tubular body 12 and interior tubular body 13.


In some embodiments, the cap 710 can include an internal taper 714 that reduces in diameter. As shown in FIG. 1J, the internal taper 714 can accommodate a flared end 722 of the exterior tubular body 12. FIG. 1K illustrates a side view of an embodiment of the exterior tubular body 12. As illustrated, the exterior tubular body 12 can include a distal end 726 and a proximal end 728. In some embodiments, the flared end 722 of the exterior tubular body 12 can be located at the proximal end 728. In some examples, the distal end 736 of the manifold body 730 can, when secured within the cap 710, be configured to engage with and secure the flared end 722 of the exterior tubular body 12. As the distal end 736 of the manifold body 730 is rotated within the cap 710, the distal end 736 of the manifold body 730 can apply pressure to the flared end 722 to form a seal 724. As will be discussed in more detail below, the seal 724 can allow fluid to be pumped into the exterior tubular body 12 and prevent fluid from leaking out of the exterior tubular body 12.


In some examples, as shown in FIG. 1J, the exterior tubular body 12 can be disposed about the interior tubular body 13. As discussed above, the interior tubular body 13 can be configured to accommodate the inner core 706. In some embodiments, as will be discussed in more detail below, the interior tubular body 13 can provide for a coolant to flow through the interior tubular body 13 to maintain the temperature of the inner core 706. In some embodiments, as will be discussed in more detail below, the exterior surface of the interior tubular body 13 and the interior surface of the exterior tubular body 12 can provide for a drug or therapeutic compound to flow through.


Turning next to FIG. 1I, illustrated is a cross-section along circle A-A of the manifold body 730 of the hub 745. In some embodiments, the proximal end 738 of the manifold body 730 can be configured to engage with and secure the interior tubular body 13. In some examples, the proximal end 738 of the manifold body 730 can include internal threads 732 that are disposed along the inner surface of the manifold body 730. In some embodiments, the proximal end of the interior tubular body 13 can be engaged with a threaded insert 790. The external threads 792 of the threaded insert 790 can be rotated to engage with the internal threads 732 of the manifold body 730.


In some embodiments, the manifold body 730 can include an internal taper 733 that reduces in diameter. As shown in FIG. 1I, the internal taper 733 can accommodate a flared end 782 of the interior tubular body 13. In some examples, the distal end of the threaded insert 790 can, when secured within the manifold body 730, be configured to engage with and secure the flared end 782 of the interior tubular body 13. As the threaded insert 790 is secured within the proximal end 738 of the manifold body 730, the distal end of the threaded insert 790 can apply pressure to the flared end 782 to form a seal 784. As will be discussed in more detail below, the seal 784 can prevent fluid from leaking out of the interior tubular body 13.


As noted above, the hub 745 can include a number of openings to allow access to the interior of the exterior tubular body 12 and the interior tubular body 13 as shown in FIGS. 2 and 2A. In some embodiments, the hub 745 can include the first barb inlet 740. The first barb inlet 740 can be located near the distal end 736 of the manifold body 730. In some embodiments, the first barb inlet 740 can be fluidly connected to the opening between the interior surface of the exterior tubular body 12 and the exterior surface of the interior tubular body 13. This can be, for example, the asymmetric gap 52 of FIG. 2. The first barb inlet 740 can be fluidly connected to a drug inlet tube 760 and allow a drug or a therapeutic compound to flow from the drug inlet tube 760 and into the exterior tubular body 12 such that the drug or therapeutic compound flows between the interior surface of the exterior tubular body 12 and the exterior surface of the interior tubular body 13.


In some examples, as illustrated in FIGS. 1G-1H, the hub 745 can include the second barb inlet 750. The second barb inlet 750 can be located near the proximal end 738 of the manifold body 730. In some embodiments, the second barb inlet 750 can be fluidly connected to the interior of the interior tubular body 13. This can be, for example, through the central lumen as illustrated in FIG. 2. The second barb inlet 750 can be fluidly connected to a coolant inlet tube 770 and allow a cooling fluid to flow through the interior tubular body 13. As noted above, in some examples, the cooling fluid can help to maintain the temperature of the inserted inner core.


In some embodiments, as illustrated in FIGS. 1G-1H, the hub 745 can include a proximal access port 755 that can provide access to the interior of the interior tubular body 13. In some embodiments, the proximal access port 755 can be configured to allow an inner core (for example the inner core 34 of FIG. 2 or the inner core 706 of FIG. 2A) to be inserted into the ultrasonic catheter 700.



FIGS. 1L-1O illustrate another embodiment of hub 845 which can be used with any of the embodiments described herein. In some embodiments, the ultrasonic catheter 800 can include a hub 845, an exterior tubular body 12, an interior tubular body 13, and a plurality of inlets. For example, the ultrasonic catheter 800 can include a first barb inlet 822, a second barb inlet 832, and a proximal access port 855.


In some embodiments, the hub 845 of the ultrasonic catheter 800 can be composed of a plurality of nested components that are secured together. In some examples, the various components of the hub 845 can be composed of a polycarbonate. As will be discussed in more detail below, the hub 845 can include an external overmold that provides an easy and secure way of attaching the various components of the hub 845. As illustrated in FIG. 1L-1M, in some examples, the hub 845 can be composed of a manifold cap 810, a distal manifold 820, a proximal manifold 830, and an overmold 860. A cross-section of each of the junctions between each of the components of the hub 845 is illustrated in greater detail in FIGS. 1N-1O.


Turning first to FIG. 1O, illustrated is a cross-section along circle C-C of the manifold cap 810 in FIG. 1M. In some embodiments, the manifold cap 810 is disposed about a distal end 824 of the distal manifold 820. As illustrated, in some examples, the manifold cap 810 is press fit 868 about the distal end 824 of the distal end 824.


In some embodiments, the manifold cap 810 can include an internal taper 812 that reduces in diameter. As shown in FIGS. 1M and 1O, the internal taper 812 can accommodate a flared end 842 of the exterior tubular body 12. In some examples, when the distal end 824 of the distal manifold 820 is secured within the manifold cap 810, the distal manifold 820 can be configured to engage with and secure the flared end 842 of the exterior tubular body 12. In some embodiments, as the distal end 824 of the distal manifold 820 is inserted within the manifold cap 810, the distal end 824 of the distal manifold 820 can apply pressure to the flared end 842 to form a seal 862. As will be discussed in more detail below, the seal 862 can allow fluid to be pumped into the exterior tubular body 12 and prevent fluid from leaking out of the exterior tubular body 12.


In some examples, as shown in FIGS. 1M and 1O, the exterior tubular body 12 can be disposed about the interior tubular body 13. As discussed above, the interior tubular body 13 can be configured to accommodate an inner core. In some embodiments, as will be discussed in more detail below, the interior tubular body 13 can provide for a coolant to flow through the interior tubular body 13 to maintain the temperature of the inserted inner core. In some embodiments, as will be discussed in more detail below, the exterior surface of the interior tubular body 13 and the interior surface of the exterior tubular body 12 can provide for a drug or therapeutic compound to flow through.


Turning next to FIGS. 1M-1N, illustrated is a cross-section along circle B-B of the connection between the proximal manifold 830 and the distal manifold 820 of the hub 845. In some embodiments, the proximal end 828 of the distal manifold 820 can be disposed about the distal end 834 of the proximal manifold 830. In some examples, the distal manifold 820 is press fit 866 about the proximal manifold 830.


In some embodiments, the proximal end 828 of the distal manifold 820 can be configured to engage with and secure the interior tubular body 13. In some embodiments, the distal manifold 820 can include an internal taper 823 that reduces in diameter. As shown in FIG. 1N, the internal taper 823 can accommodate a flared end 852 of the interior tubular body 13. In some examples, the distal end 834 of the proximal manifold 830 can, when secured within the proximal end 828 of the distal manifold 820, be configured to engage with and secure the flared end 852 of the interior tubular body 13. In some embodiments, the distal end 834 of the proximal manifold 830 can apply pressure to the flared end 852 to form a seal 862. As will be discussed in more detail below, the seal 862 can prevent fluid from leaking out of the interior tubular body 13.


As noted above, the hub 845 can include a number of openings to allow access to the interior of the exterior tubular body 12 and the interior tubular body 13 as shown in FIGS. 2 and 2A. In some embodiments, the hub 845 can include the first barb inlet 822. The first barb inlet 822 can be located on the distal manifold 820. In some embodiments, the first barb inlet 822 can be fluidly connected to the opening between the interior surface of the exterior tubular body 12 and the exterior surface of the interior tubular body 13. This can be, for example, the asymmetric gap 52 of FIG. 2. In some embodiments, the drug inlet tube 826 can be disposed about the first barb inlet 822. The first barb inlet 822 can be fluidly connected to the drug inlet tube 826 and allow a drug or a therapeutic compound to flow from the drug inlet tube 826 and into the exterior tubular body 12 such that the drug or therapeutic compound flows between the interior surface of the exterior tubular body 12 and the exterior surface of the interior tubular body 13.


In some examples, as illustrated in FIG. 1M, the hub 845 can include the second barb inlet 832. The second barb inlet 832 can be located on the proximal manifold 830. In some embodiments, the proximal manifold 830 can be fluidly connected to the interior of the interior tubular body 13. This can be, for example, through the central lumen as illustrated in FIG. 2. In some embodiments, the coolant inlet tube 836 can be disposed about the second barb inlet 832. The second barb inlet 832 can be fluidly connected to the coolant inlet tube 836 and allow a cooling fluid to flow through the interior tubular body 13. As noted above, in some examples, the cooling fluid can help to maintain the temperature of the inserted inner core.


In some embodiments, as illustrated in FIG. 1M, the hub 845 can include a proximal access port 855 that can provide access to the interior tubular body 13. In some examples, the proximal access port 855 can be configured to allow an inner core (for example the inner core 34 of FIG. 2 or the inner core 706 of FIG. 2A) to be inserted into the ultrasonic catheter 800.


As discussed above, in some embodiments, the hub 845 can include an overmold 860. In some examples, the overmold 860 can be composed of a co-polyester. In some embodiments, the overmold 860 can be composed of a polyamide. The overmold 860 can be configured to seal and secure the various components of the hub 845.


Details and various embodiments of the inner core 34 and its operation of can be found in several patents and patent applications filed by EKOS Corporation of Bothell, Wash. including U.S. Pat. No. 7,220,239 and U.S. Patent Publication No. 2008/0171965, which are hereby incorporated by reference in their entirety.


As shown in the cross-section illustrated in FIG. 4, which is taken along lines 4-4 in FIG. 3, the inner core 34 can have a cylindrical shape, with an outer diameter that permits the inner core 34 to be inserted into the central lumen 51 of the interior tubular body 13 via the proximal access port 31. Suitable outer diameters of the inner core 34 include, but are not limited to, about 0.010 inches to about 0.100 inches (about 0.025 cm to about 0.254 cm). In other embodiments, the outer diameter of the inner core 34 can be between about 0.020 inches and about 0.080 inches (about 0.051 cm to about 0.20 cm). In other embodiments, the inner core 34 can have an outer diameter of about 0.035 inches (about 0.089 cm).


Still referring to FIG. 4, the inner core 34 can include a cylindrical outer body 35 that houses the ultrasound assembly 42. The ultrasound assembly 42 can include wiring and ultrasound radiating members, described in greater detail in FIGS. 5 through 7D, such that the ultrasound assembly 42 is capable of radiating ultrasonic energy from the energy delivery section 41 of the inner core 34. The ultrasound assembly 42 can be electrically connected to the backend hub 33, where the inner core 34 can be connected to a control system 100 via cable and through a connector (not shown). In one arrangement, an electrically insulating potting material 43 fills the inner core 34, surrounding the ultrasound assembly 42, thus preventing or limiting movement of the ultrasound assembly 42 with respect to the outer body 35. In one embodiment, the thickness of the outer body 35 is between about 0.0002 inches and about 0.010 inches (between about 0.0005 cm and about 0.025 cm). In another embodiment, the thickness of the outer body 35 is between about 0.0002 inches and about 0.005 inches (between about 0.0005 cm and about 0.01 cm). In yet another embodiment, the thickness of the outer body 35 is about 0.0005 inches (about 0.001 cm).


In some embodiments, the ultrasound assembly 42 comprises a plurality of ultrasound radiating members 40 that are divided into one or more groups. For example, FIGS. 5 and 6 are schematic wiring diagrams illustrating one technique for connecting five groups of ultrasound radiating members 40 to form the ultrasound assembly 42. As illustrated in FIG. 5, the ultrasound assembly 42 can include five groups G1, G2, G3, G4, and G5 of ultrasound radiating members 40 that can be electrically connected to each other. The five groups are also electrically connected to the control system 100. In some embodiments, two, three, or four groups of ultrasound radiating member 40 may be electrically connected to each other and the control system 100.


In some embodiments, the ultrasound assembly 42 comprises five or less (i.e., one, two, three, four, or five) ultrasound radiating members 40. The ultrasound radiating members 40 may be divided into one or more groups as described above. The reduced or limited number of ultrasound radiating members 40 can allow the ultrasound assembly 42 to be driven at a higher power.


As used herein, the terms “ultrasonic energy”, “ultrasound” and “ultrasonic” are broad terms, having their ordinary meanings, and further refer to, without limitation, mechanical energy transferred through longitudinal pressure or compression waves. Ultrasonic energy can be emitted as continuous or pulsed waves, depending on the requirements of a particular application. Additionally, ultrasonic energy can be emitted in waveforms having various shapes, such as sinusoidal waves, triangle waves, square waves, or other wave forms. Ultrasonic energy includes sound waves. In certain embodiments, the ultrasonic energy has a frequency between about 20 kHz and about 20 MHz. For example, in one embodiment, the waves have a frequency between about 500 kHz and about 20 MHz. In another embodiment, the waves have a frequency between about 1 MHz and about 3 MHz. In yet another embodiment, the waves have a frequency of about 2 MHz. The average acoustic power is between about 0.01 watts and 300 watts. In one embodiment, the average acoustic power is about 16 watts.


As used herein, the term “ultrasound radiating member” refers to any apparatus capable of producing ultrasonic energy. For example, in one embodiment, an ultrasound radiating member comprises an ultrasonic transducer, which converts electrical energy into ultrasonic energy. A suitable example of an ultrasonic transducer for generating ultrasonic energy from electrical energy includes, but is not limited to, piezoelectric ceramic oscillators. Piezoelectric ceramics typically comprise a crystalline material, such as quartz, that changes shape when an electrical current is applied to the material. This change in shape, made oscillatory by an oscillating driving signal, creates ultrasonic sound waves. In other embodiments, ultrasonic energy can be generated by an ultrasonic transducer that is remote from the ultrasound radiating member, and the ultrasonic energy can be transmitted, via, for example, vibration through a wire that is coupled to the ultrasound radiating member.


Still referring to FIG. 5, the control circuitry 100 can include, among other things, a voltage source 102. The voltage source 102 can comprise a positive terminal 104 and a negative terminal 106. The negative terminal 106 is connected to common wire 108, which connects the five groups G1-GS of ultrasound radiating members 40 in series. The positive terminal 104 can be connected to a plurality of lead wires 110, which each connect to one of the five groups G1-GS of ultrasound radiating members 40. Thus, under this configuration, each of the five groups GI-GS, one of which is illustrated in FIG. 6, can be connected to the positive terminal 104 via one of the lead wires 110, and to the negative terminal 106 via the common wire 108. The control circuitry can be configured as part of the control system 100 and can include circuits, control routines, controllers etc. configured to vary one or more power parameters used to drive ultrasound radiating members 40.


Referring now to FIG. 6, in one embodiment, each group G1-GS can comprise a plurality of ultrasound radiating members 40. Each of the ultrasound radiating members 40 can be electrically connected to the common wire 108 and to the lead wire 110 via one of two positive contact wires 112. Thus, when wired as illustrated, a constant voltage difference will be applied to each ultrasound radiating member 40 in the group. Although the group illustrated in FIG. 6 comprises twelve ultrasound radiating members 40, one of ordinary skill in the art will recognize that more or fewer ultrasound radiating members 40 can be included in the group. Likewise, more or fewer than five groups can be included within the ultrasound assembly 42 illustrated in FIG. 5.



FIG. 7A illustrates one technique for arranging the components of the ultrasound assembly 42 (as schematically illustrated in FIG. 5) into the inner core 34 (as schematically illustrated in FIG. 4). FIG. 7A illustrates a cross-sectional view of the ultrasound assembly 42 taken within group GI in FIG. 5, as indicated by the presence of four lead wires 110. For example, if a cross-sectional view of the ultrasound assembly 42 was taken within group G4 in FIG. 5, only one lead wire 110 would be present (that is, the one lead wire connecting group G5).


Referring still to FIG. 7A, the common wire 108 can include an elongate, flat piece of electrically conductive material in electrical contact with a pair of ultrasound radiating members 40. Each of the ultrasound radiating members 40 can also be in electrical contact with a positive contact wire 312. Because the common wire 108 is connected to the negative terminal 106, and the positive contact wire 312 is connected to the positive terminal 104, a voltage difference can be created across each ultrasound radiating member 40. In some embodiments, the lead wires 110 can be separated from the other components of the ultrasound assembly 42, thus preventing interference with the operation of the ultrasound radiating members 40 as described above. For example, in some embodiments, the inner core 34 is filled with an insulating potting material 43, thus deterring unwanted electrical contact between the various components of the ultrasound assembly 42.



FIGS. 7B and 7C illustrate cross-sectional views of the inner core 34 of FIG. 7A taken along lines 7B-7B and 7C-7C, respectively. As illustrated in FIG. 7B, the ultrasound radiating members 40 are mounted in pairs along the common wire 108. The ultrasound radiating members 40 are connected by positive contact wires 112, such that substantially the same voltage is applied to each ultrasound radiating member 40. As illustrated in FIG. 7C, the common wire 108 can include wide regions 108W upon which the ultrasound radiating members 40 can be mounted, thus reducing the likelihood that the paired ultrasound radiating members 40 will short together. In certain embodiments, outside the wide regions 108W, the common wire 108 may have a more conventional, rounded wire shape.


In a modified embodiment, such as illustrated in FIG. 7D, the common wire 108 can be twisted to form a helical shape before being fixed within the inner core 34. In such embodiments, the ultrasound radiating members 40 are oriented in a plurality of radial directions, thus enhancing the radial uniformity of the resulting ultrasonic energy field.


One of ordinary skill in the art will recognize that the wiring arrangement described above can be modified to allow each group G1, G2, G3, G4, G5 to be independently powered. Specifically, by providing a separate power source within the control system 100 for each group, each group can be individually turned on or off, or can be driven with an individualized power. This provides the advantage of allowing the delivery of ultrasonic energy to be “turned off” in regions of the treatment site where treatment is complete, thus preventing deleterious or unnecessary ultrasonic energy to be applied to the patient.


The embodiments described above, and illustrated in FIGS. 5 through 7, illustrate a plurality of ultrasound radiating members grouped spatially. That is, in such embodiments, all of the ultrasound radiating members within a certain group are positioned adjacent to each other, such that when a single group is activated, ultrasonic energy is delivered at a specific length of the ultrasound assembly. However, in modified embodiments, the ultrasound radiating members of a certain group may be spaced apart from each other, such that the ultrasound radiating members within a certain group are not positioned adjacent to each other. In such embodiments, when a single group is activated, ultrasonic energy can be delivered from a larger, spaced apart portion of the energy delivery section. Such modified embodiments may be advantageous in applications wherein it is desired to deliver a less focused, more diffuse ultrasonic energy field to the treatment site.


In some embodiments, the ultrasound radiating members 40 comprise rectangular lead zirconate titanate (“PZT”) ultrasound transducers. In some embodiments, the ultrasound transducer may have dimensions of about 0.017 inches by about 0.010 inches by about 0.080 inches (about 0.043 cm by about 0.025 cm by about 0.20 cm). In other embodiments, other configuration may be used. For example, disc-shaped ultrasound radiating members 40 can be used in other embodiments. In an embodiment, the common wire 108 comprises copper, and is about 0.005 inches (about 0.01 cm) thick, although other electrically conductive materials and other dimensions can be used in other embodiments. Lead wires 110 can comprise 36 gauge electrical conductors, while positive contact wires 112 can be 42 gauge electrical conductors. However, one of ordinary skill in the art will recognize that other wire gauges can be used in other embodiments.


As described above, suitable frequencies for the ultrasound radiating member 40 include, but are not limited to, from about 20 kHz to about 20 MHz. In one embodiment, the frequency is between about 500 kHz and 20 MHz, and in another embodiment 1 MHz and 3 MHz. In yet another embodiment, the ultrasound radiating members 40 are operated with a frequency of about 2 MHz.



FIG. 8 illustrates the inner core 34 positioned within the exterior tubular body 12 along a cross-sectional line similar to 2-2 in FIG. 1C. Details of the ultrasound assembly 42, provided in FIG. 7A, are omitted for clarity. As described above, the inner core 34 can be slid within the central lumen 51 of the interior tubular body 13, thereby allowing the inner core 34 to be positioned within the energy delivery section 18. For example, in an embodiment, the materials comprising the inner core energy delivery section 41, the tubular body energy delivery section 18, and the potting material 43 all comprise materials having similar acoustic impedance, thereby minimizing ultrasonic energy losses across material interfaces.



FIG. 8 further illustrates placement of fluid delivery ports 58 within the tubular body energy delivery section 18. As illustrated, holes or slits can be formed from the fluid delivery lumen 30 through the exterior tubular body 12, thereby permitting fluid flow from the asymmetrical gap 52 to the treatment site. Thus, a source of therapeutic compound coupled to the inlet port 32 can provide a hydraulic pressure which drives the therapeutic compound through the asymmetric gap 52 in the fluid delivery lumen 30 and out the fluid delivery ports 58. Thus, inlet port 32 is a first fluid injection port in fluid communication with the asymmetric gap 52.


In some embodiments, as illustrated in FIG. 8, the fluid delivery lumen 30 is not evenly spaced around the circumference of the exterior tubular body 12. As discussed, in some embodiments, the exterior tubular body 12 further accommodates the temperature sensor 20. As noted above, the temperature sensor can be a flexcircuit such as the flexcircuit 220 described above with respect to FIGS. 2A and 2B or flexcircuit 320 described with respect to FIGS. 12A and 12B. In some embodiments, the temperature sensor 20 can contact the interior tubular body 13 to bias the interior tubular body 13 against the interior surface of the exterior tubular body 12 and/or to one side of the fluid delivery lumen 30.


In some examples, the configuration of the interior tubular body 13 and temperature sensor 20 can provide a manufacturing benefit as it allows for the construction of the catheter 10 by simply inserting the interior tubular body 13 and temperature sensor 20 into the exterior tubular body 12. This can allow the gap 52 to form between the exterior surface of the interior tubular body 13 and the interior surface of the exterior tubular body 12. In some embodiments, the size, location, and geometry of the fluid delivery ports 58 can be selected to provide uniform fluid flow from the fluid delivery ports 58 to the treatment site. For example, in one embodiment, the fluid delivery ports 58 closer to the proximal region of the energy delivery section 18 have smaller diameters than fluid delivery ports 58 closer to the distal region of the energy delivery section 18, thereby allowing uniform delivery of fluid across the entire energy delivery section 18. The configuration of the interior tubular body 13 can also provide better kink resistance and can potentially reduce the ultrasound attenuation. In some embodiments where the fluid delivery ports 58 have similar sizes along the length of the exterior tubular body 12, the fluid delivery ports 58 have a diameter between about 0.0005 inches to about 0.0050 inches (between about 0.001 cm to about 0.013 cm). In another embodiment in which the size of the fluid delivery ports 58 changes along the length of the exterior tubular body 12, the fluid delivery ports 58 have a diameter between about 0.001 inches to about 0.005 inches (between about 0.002 to about 0.01 cm) in the proximal region of the energy delivery section 18, and between about 0.0020 inches to about 0.005 inches (between about 0.005 cm to 0.01 about cm) in the distal region of the energy delivery section 18. The increase in size between fluid delivery ports 58 depends on the material composition of the exterior tubular body 12, and on the gap 52. In some embodiments, the fluid delivery ports 58 can be created in the exterior tubular body 12 by punching, drilling, burning, or ablating (e.g. with a laser), or by any other suitable methods. The drug or therapeutic compound flowing along the length of the exterior tubular body 12 can be increased by increasing the density of the number of fluid delivery ports 58 toward the distal region 15 of the exterior tubular body 12.


It should be appreciated that it may be desirable to provide non-uniform fluid flow from the fluid delivery ports 58 to the treatment site. In such embodiment, the size, location and geometry of the fluid delivery ports 58 can be selected to provide such non-uniform fluid flow.


Referring still to FIG. 8, placement of the inner core 34 within the exterior tubular body 12 further defines cooling fluid lumen 44. The cooling fluid lumen 44 can be formed between outer surface 39 of the inner core 34 and the inner surface of the interior tubular body 13. In some embodiments, a cooling fluid can be introduced through the proximal access port 31 such that the cooling fluid flow is produced through cooling fluid lumen 44 and out the distal exit port 29 (see FIG. 1C). Thus, in some embodiments, the proximal access port 31 is a fluid injection port in fluid communication with an interior of the interior tubular body 13. In the illustrated arrangement, a cooling fluid can be introduced through the port 46 such that the cooling fluid flow is produced through cooling fluid lumen 44 and out the distal exit port 29. The cooling fluid lumen 44 can be evenly spaced around the inner core 34 so as to provide uniform cooling fluid flow over the inner core 34. Such a configuration can be desirable to remove unwanted thermal energy at the treatment site. As will be explained below, the flow rate of the cooling fluid and the power to the ultrasound assembly 42 can be adjusted to maintain the temperature of the inner core 34 in the energy delivery section 41 within a desired range.


In some embodiments, the inner core 34 can be rotated or moved within the interior tubular body 13. Specifically, movement of the inner core 34 can be accomplished by maneuvering the proximal hub 37 while holding the backend hub 33 stationary. The inner core outer body 35 is at least partially constructed from a material that provides enough structural support to permit movement of the inner core 34 within the interior tubular body 13 without kinking of the interior tubular body 13 without kinking of the interior tubular body 13. Additionally, the inner core outer body 35 can include a material having the ability to transmit torque. Suitable materials for the outer body 35 can include, but are not limited to, polymides, polyesters, polyurethanes, thermoplastic elastomers and braided polyimides.


In one embodiment, the fluid delivery lumen 30 and the cooling fluid lumen 44 are open at the distal end of the exterior tubular body 12, thereby allowing the drug or therapeutic compound and the cooling fluid to pass into the patients' vasculature at the distal exit port. Or, if desired, the fluid delivery lumen 30 can be selectively occluded at the distal end of the exterior tubular body 12, thereby providing additional hydraulic pressure to drive the therapeutic compound out of the fluid delivery ports 58. In either configuration, the inner core 34 can prevented from passing through the distal exit port by providing the inner core 34 with a length that is less than the length of the tubular body. In other embodiments, a protrusion is formed on the internal side of the tubular body in the distal region 15, thereby preventing the inner core 34 from passing through the distal exit port.


In still other embodiments, the catheter 10 further includes an occlusion device (not shown) positioned at the distal exit port 29. The occlusion device can have a reduced inner diameter that can accommodate a guidewire, but that is less than the inner diameter of the central lumen 51. Thus the inner core 34 is prevented from extending through the occlusion device and out the distal exit port 29. For example, suitable inner diameters for the occlusion device include, but are not limited to, about 0.005 inches to about 0.050 inches (about 0.01 cm to about 0.13 cm). In other embodiments, the occlusion device has a closed end, thus preventing cooling fluid from leaving the catheter 10, and instead recirculating to the proximal region 14 of the exterior tubular body 12. These and other cooling fluid flow configurations permit the power provided to the ultrasound assembly 42 to be increased in proportion to the cooling fluid flow rate. Additionally, certain cooling fluid flow configurations can reduce exposure of the patient's body to cooling fluids.


In certain embodiments, as illustrated in FIG. 8, the exterior tubular body 12 can include a temperature sensor 20, which can be located adjacent the interior tubular body 13. In such embodiments, the proximal region 14 of the exterior tubular body 12 includes a temperature sensor lead which can be incorporated into cable 45 (illustrated in FIG. 1B). As discussed above, in some embodiments the temperature sensor 20 can have a minimal profile such that it can be placed within the exterior tubular body 12 adjacent the interior tubular body 13. In some embodiments, to have a minimal profile, the temperature sensor 20 can be made of a flexible circuit as described above. For example, the temperature sensor 20 can be the flexcircuit 220 of FIGS. 2A and 2B or the flexcircuit 320 of FIGS. 12A and 12B. In other embodiments, temperature sensor 20 can include, but is not limited to, temperature sensing diodes, thermistors, thermocouples, resistance temperature detectors (“RTDs”) and fiber optic temperature sensors which use thermalchromic liquid crystals. In some embodiments, suitable temperature sensor 20 geometries can include a strip that lies along the length of the exterior tubular body 12. In other embodiments, suitable temperature sensor 20 geometries can include, but are not limited to, a point, a patch or a stripe. In some embodiments, to provide for easy of assembly, the temperature sensor(s) 20 can be positioned within the exterior tubular body 12 (as illustrated), and/or within one or more of the cooling fluid lumen 44.



FIG. 9 illustrates one embodiment for electrically connecting a plurality of temperature sensor 20. In such embodiments, each temperature sensor 20 is coupled to a common wire 61 (e.g., a Constantan trace) and is associated with an individual return wire 62. Accordingly, n+1 wires can be used to independently sense the temperature at n distinct temperature sensor 20. The temperature at a particular temperature sensor 20 can be determined by closing a switch 64 to complete a circuit between that thermocouple's individual return wire 62 and the common wire 61. In embodiments wherein the temperature sensor 20 comprise thermocouples, the temperature can be calculated from the voltage in the circuit using, for example, a sensing circuit 63, which can be located within the external control circuitry 100.


In other embodiments, each temperature sensor 20 is independently wired. In such embodiments, 2n wires run through the exterior tubular body 12 to independently sense the temperature at n independent temperature sensor 20.



FIG. 10 illustrates one embodiment of a feedback control system 68 that can be used with the catheter 10. The feedback control system 68 can be integrated into a control system that is connected to the inner core 34 via cable and/or the temperature sensor 20 via connector 100 (as illustrated in FIG. 1B). The feedback control system 68 allows the temperature at each temperature sensor 20 to be monitored and allows the output power of the energy source to be adjusted accordingly. A physician can, if desired, override the closed or open loop system.


The feedback control system 68 can include an energy source 70, power circuits 72 and a power calculation device 74 that is coupled to the ultrasound radiating members 40. A temperature measurement device 76 can coupled to the temperature sensor 20 in the exterior tubular body 12. A processing unit 78 can be coupled to the power calculation device 74, the power circuits 72 and a user interface and display 80.


In operation, the temperature at each temperature sensor 20 can be determined by the temperature measurement device 76. The processing unit 78 receives each determined temperature from the temperature measurement device 76. The determined temperature can then be displayed to the user at the user interface and display 80.


The processing unit 78 comprises logic for generating a temperature control signal. The temperature control signal can be proportional to the difference between the measured temperature and a desired temperature. The desired temperature can be determined by the user (at set at the user interface and display 80) or can be preset within the processing unit 78.


The temperature control signal can be received by the power circuits 72. In some embodiments, the power circuits 72 can be configured to adjust the power level, voltage, phase and/or current of the electrical energy supplied to the ultrasound radiating members 40 from the energy source 70. For example, when the temperature control signal is above a particular level, the power supplied to a particular group of ultrasound radiating members 40 can be reduced in response to that temperature control signal. Similarly, when the temperature control signal is below a particular level, the power supplied to a particular group of ultrasound radiating members 40 can be increased in response to that temperature control signal. After each power adjustment, the processing unit 78 can be configured to monitor the temperature sensor 20 and produces another temperature control signal which is received by the power circuits 72.


The processing unit 78 can further include safety control logic. The safety control logic detects when the temperature at a temperature sensor 20 has exceeded a safety threshold. The processing unit 78 can then provide a temperature control signal which causes the power circuits 72 to stop the delivery of energy from the energy source 70 to that particular group of ultrasound radiating members 40.


Because, in certain embodiments, the ultrasound radiating members 40 are mobile relative to the temperature sensor 20, it can be unclear which group of ultrasound radiating members 40 should have a power, voltage, phase and/or current level adjustment. Consequently, each group of ultrasound radiating member 40 can be identically adjusted in certain embodiments. In a modified embodiment, the power, voltage, phase, and/or current supplied to each group of ultrasound radiating members 40 is adjusted in response to the temperature sensor 20 which indicates the highest temperature. Making voltage, phase and/or current adjustments in response to the temperature sensed by the temperature sensor 20 indicating the highest temperature can reduce overheating of the treatment site.


The processing unit 78 can also receive a power signal from a power calculation device 74. The power signal can be used to determine the power being received by each group of ultrasound radiating members 40. The determined power can then be displayed to the user on the user interface and display 80.


As described above, the feedback control system 68 can be configured to maintain tissue adjacent to the energy delivery section 18 below a desired temperature. For example, it can be generally desirable to prevent tissue at a treatment site from increasing more than 6° C. As described above, the ultrasound radiating members 40 can be electrically connected such that each group of ultrasound radiating members 40 generates an independent output. In certain embodiments, the output from the power circuit maintains a selected energy for each group of ultrasound radiating members 40 for a selected length of time.


The processing unit 78 can comprise a digital or analog controller, such as a computer with software. When the processing unit 78 is a computer it can include a central processing unit (“CPU”) coupled through a system bus. As is well known in the art, the user interface and display 80 can comprise a mouse, a keyboard, a disk drive, a display monitor, a nonvolatile memory system, or any another. In some embodiments, the bus can be coupled to a program memory and a data memory.


In lieu of the series of power adjustments described above, a profile of the power to be delivered to each group of ultrasound radiating members 40 can be incorporated into the processing unit 78, such that a preset amount of ultrasonic energy to be delivered is pre-profiled. In such embodiments, the power delivered to each group of ultrasound radiating members 40 can then be adjusted according to the preset profiles.


The ultrasound radiating members can be operated in a pulsed mode. For example, in one embodiment, the time average electrical power supplied to the ultrasound radiating members can be between about 0.1 watts and 2 watts and can be between about 0.5 watts and 1.5 watts. In other embodiments, the time average electrical power supplied to the ultrasound radiating members is between about 0.001 watts and about 5 watts and can be between about 0.05 watts and about 3 watts. In some embodiments, the time average electrical power can be approximately 0.6 watts or 1.2 watts to a pair of ultrasound radiating members. In other embodiments, the time average electrical power over treatment time can be approximately 0.45 watts or 1.2 watts to a pair of ultrasound radiating members.


The duty cycle can be between about 1% and 50%. In some embodiments, the duty cycle can be between about 5% and 25%. In certain embodiments, the duty ratio can be approximately 7.5% or 15%. In other embodiments, the duty cycle can be between about 0.01% and about 90% and can be between about 0.1% and about 50%. In certain embodiments, the duty ratio can be approximately 7.5%, 15% or a variation between 1% and 30%. In some embodiments, the pulse averaged power to a pair of ultrasound radiating members can be between about 0.1 watts and 20 watts and can further be between approximately 5 watts and 20 watts. In certain embodiments, the pulse averaged power to a pair of ultrasound radiating members can be approximately 8 watts and 16 watts. In some embodiments, the pulse averaged electrical power to a pair of ultrasound radiating members can be between about 0.01 watts and about 20 watts and can be between approximately 0.1 watts and 20 watts. In other embodiments, the pulse averaged electrical power to a pair of ultrasound radiating members is approximately 4 watts, 8 watts, 16 watts, or a variation of 1 to 8 watts. The amplitude during each pulse can be constant or varied.


As described above, the amplitude, pulse width, pulse repetition frequency, average acoustic pressure or any combination of these parameters can be constant or varied during each pulse or over a set of portions. In a non-linear application of acoustic parameters the above ranges can change significantly. Accordingly, the overall time average electrical power over treatment time may stay the same but not real-time average power.


In some embodiments, the pulse repetition rate can be between about 5 Hz and 150 Hz and can further be between about 10 Hz and 50 Hz. In some embodiments, the pulse repetition rate is approximately 30 Hz. In other embodiments, the pulse repetition can be between about 1 Hz and about 2 kHz and more can be between about 1 Hz and about 50 Hz. In certain embodiments, the pulse repetition rate can be approximately 30 Hz, or a variation of about 10 to about 40 Hz. The pulse duration can be between about 1 millisecond and 50 milliseconds and can be between about 1 millisecond and 25 milliseconds. In certain embodiments, the pulse duration can be approximately 2.5 milliseconds or 5 milliseconds. In other embodiments, the pulse duration or width can be between about 0.5 millisecond and about 50 milliseconds and can be between about 0.1 millisecond and about 25 milliseconds. In certain embodiments, the pulse duration can be approximately 2.5 milliseconds, 5 or a variation of 1 to 8 milliseconds. In certain embodiments, the average acoustic pressure can be between about 0.1 to about 20 MPa or in another embodiment between about 0.5 or about 0.74 to about 1.7 MPa. In one particular embodiment, the transducers can be operated at an average power of approximately 0.6 watts, a duty cycle of approximately 7.5%, a pulse repetition rate of 30 Hz, a pulse average electrical power of approximately 8 watts and a pulse duration of approximately 2.5 milliseconds. In one particular embodiment, the transducers can be operated at an average power of approximately 0.45 watts, a duty cycle of approximately 7.5%, a pulse repetition rate of 30 Hz, a pulse average electrical power of approximately 6 watts and a pulse duration of approximately 2.5 milliseconds. The ultrasound radiating member used with the electrical parameters described herein can have an acoustic efficiency greater than 50%. In some embodiments, the acoustic efficiency can be greater than 75%. The ultrasound radiating member can be formed a variety of shapes, such as, cylindrical (solid or hollow), flat, bar, triangular, and the like. The length of the ultrasound radiating member can be between about 0.1 cm and about 0.5 cm. The thickness or diameter of the ultrasound radiating members can be between about 0.02 cm and about 0.2 cm.



FIGS. 11A through 11D illustrate a method for using the ultrasonic catheter 10. As illustrated in FIG. 11A, a guidewire 84 similar to a guidewire used in typical angioplasty procedures can be directed through a patient's vessels 86 to a treatment site 88 which includes a clot 90. The guidewire 84 can be directed through the clot 90. Suitable vessels 86 can include, but are not limited to, the large periphery blood vessels of the body. Additionally, as mentioned above, the ultrasonic catheter 10 also has utility in various imaging applications or in applications for treating and/or diagnosing other diseases in other body parts.


As illustrated in FIG. 11B, the catheter 10 can be slid over and advanced along the guidewire 84 using conventional over-the-guidewire techniques with the guidewire extending through the interior tubular body 13. The catheter 10 can be advanced until the energy delivery section 18 of the exterior tubular body 12 is positioned at the clot 90. In certain embodiments, radiopaque markers (not shown) are positioned along the energy delivery section 18 of the exterior tubular body 12 to aid in the positioning of the exterior tubular body 12 of the catheter 10 within the treatment site 88.


As illustrated in FIG. 11C, the guidewire 84 can then be withdrawn from the catheter 10 by pulling the guidewire 84 from the proximal region 14 of the catheter 10 while holding the catheter stationary. This leaves catheter 10 (exterior body 12 shown in FIG. 11C) positioned at the treatment site 88.


As illustrated in FIG. 11D, the inner core 34 can then be inserted into interior tubular body 13 until the ultrasound assembly 42 is positioned at least partially within the energy delivery section 18 of the exterior tubular body 12. Once the inner core 34 is properly positioned, the ultrasound assembly 42 can be activated to deliver ultrasonic energy through the energy delivery section 18 to the clot 90. As described above, suitable ultrasonic energy is delivered with a frequency between about 20 kHz and about 20 MHz.


In a certain embodiment, the ultrasound assembly 42 comprises sixty ultrasound radiating members 40 spaced over a length of approximately 30 to 50 cm. In such embodiments, the catheter 10 can be used to treat an elongate clot 90 without requiring movement of or repositioning of the catheter 10 during the treatment. However, in some embodiments, the inner core 34 can be moved or rotated within the catheter 10 during the treatment. Such movement can be accomplished by maneuvering the proximal hub 37 of the inner core 34 while holding the backend hub 33 stationary.


Referring again to FIG. 11D, arrows 48 indicate that a cooling fluid flows through the cooling fluid lumen 44 and out the distal exit port 29. Likewise, arrows 49 indicated that a therapeutic compound flows through gap 52 in the fluid delivery lumen 30 and out the fluid delivery ports 58 to the treatment site 88. In the schematic illustrations of FIGS. 11A and 11D, the fluid delivery ports 58 are shown in a different location than illustrated in FIG. 8.


The cooling fluid can be delivered before, after, during or intermittently with the delivery of ultrasonic energy. Similarly, the therapeutic compound can be delivered before, after, during or intermittently with the delivery of ultrasonic energy. Consequently, the steps illustrated in FIGS. 11A through 11D can be performed in a variety of different orders than that described above. The therapeutic compound and ultrasonic energy can be applied until the clot 90 is partially or entirely dissolved. Once the clot 90 has been dissolved to the desired degree, the exterior tubular body 12 and the inner core 34 are withdrawn from the treatment site 88.


Pulmonary Embolism Treatment


In some embodiments, the ultrasonic catheter 10 can be configured to be introduced into the major blood vessels leading from the heart to the lungs (e.g., the pulmonary artery). In one embodiment of use, femoral venous access may be used to place the ultrasonic catheter 10 into such vessels. In such embodiments, the ultrasonic catheter 10 can be advanced through femoral access site, through the heart and into the pulmonary artery. The dimensions of the ultrasonic catheter 10 are adjusted based on the particular application for which the ultrasonic catheter 10 is to be used.


As noted above, the ultrasound catheter 10 can also be used for treating PE. The ultrasound catheter 10 can be introduced into a patient's pulmonary artery over a guidewire. The distal region 15 of the ultrasound catheter 10 is then advanced to the treatment site within the pulmonary artery. The ultrasound energy delivery section 18 of the ultrasound catheter can be positioned across the treatment site using fluoroscopic guidance via radiopaque marker located near the proximal end and the distal end of the ultrasound energy delivery section 18. Once the ultrasound catheter 10 is successfully placed, the guidewire may be removed from the ultrasound catheter 10. In the embodiments depicted in FIGS. 1-11, the elongate inner core 34 comprising at least one ultrasound radiating member 40 can then be inserted into the central lumen 51 of the ultrasound catheter 10. The at least one ultrasound radiating member 40 can be positioned along the energy delivery section 18 of the ultrasound catheter 10. In some embodiments, at least one cooling lumen 44 is formed between an outer surface 39 of the inner core 34 and an inner surface of the interior tubular body 13. The coolant infusion pump is attached to the cooling fluid inlet port 46, which is in communication with the at least one cooling fluid lumen 44. The drug infusion pump can then be connected to the fluid inlet port 32, which is in communication with the asymmetric gap 52 in the at least one fluid delivery lumen 30.


The thrombolytic drug can then be delivered to the treatment site through at least one fluid delivery lumen 30. In some embodiments, a plurality of fluid delivery ports 58 is in fluid communication with the fluid delivery lumen 30 can be located on the ultrasound catheter at the ultrasound energy delivery section 18. The drug can be infused through the fluid delivery ports 58 to the treatment site.


The ultrasound energy may be delivered to the treatment site simultaneously or intermittently with the infusion of the thrombolytic drug. In some embodiments, the ultrasound energy is emitted to the treatment site prior to the thrombolytic drug being delivered. In some embodiments, the thrombolytic drug is delivered to the treatment site prior to the ultrasound energy being emitted. The ultrasound energy may be emitted according to the manner described above. In some embodiment, the power parameter and the physiological parameter of at least one ultrasound radiating member 40 may be varied as described above.


In some embodiments, the elongate inner core 34 may comprise five or less (i.e., one, two, three, four, or five) ultrasound radiating members 40. In some variants, by limiting the number of the ultrasound radiating members 40, it is can be possible to drive the ultrasound radiating members at a higher power for PE treatments.


High intensity ultrasound catheter may also be especially effective in treating pulmonary embolism. In some embodiments, the size of one or more ultrasound radiating members 40 positioned in the elongate inner core 34 can be increased to generate high intensity ultrasound. In other words, larger ultrasound radiating members can be used for this purpose. In some embodiments, positioning the ultrasound radiating members less than 1 cm apart can result in higher intensity ultrasound output.


Without being bound to the theory, the ultrasound can prepare the clot by unwinding the fibrin strands and increasing the permeability of the clot. Acoustic pressure waves and micro-streaming force the delivered drug into the clot, quickly permeating the clot with drug. As the drug is absorbed into the clot it binds with exposed plasminogen receptor sites. Once bound in the clot, the drug is no longer in free circulation, does not pass through the liver and is not metabolized.


In some embodiments, recombinant tissue plasminogen activator (rt-PA or Actilyse®) can be used with the ultrasound catheter 10 for the treatment of pulmonary embolism. The effective infusion dosage may range from about 0.12 mg/hr to about 2 mg/hr, from about 0.2 mg/hr to about 1.5 mg/hr, from about 0.5 mg/hr to about 1.5 mg/hr, or from about 1 mg/hr to about 2 mg/hr. The rt-PA maximum total infusion dose may be from about 10 mg to about 30 mg, from about 10 mg to about 20 mg, or about 25 mg. In some embodiment, as rt-PA is infused at a rate of about 1 mg/hr to about 2 mg/hr for about 3 to about 5 hours, then the infusion rate is decreased to about 0.5 mg/hr for 10 hours. In some embodiments, rt-PA is infused at a rate of about 1 mg/hr to about 2 mg/hr for about 5 hours, and then the infusion rate is decreased to about 0.5 mg/hr for 10 hours.


Other potential drugs that may be used with the ultrasound catheter for treating pulmonary embolism may include fibrinolytic compounds such as urokinase (Abbokinase®, Abbott laboratories, USA), streptokinase (Streptase®, Behringwerke AG), and reteplase (Retavase™, Centocor, Inc.). The enzymatic activity and stability of these fibrinolytics (including rt-PA) are not changed after exposure to therapeutic ultrasound.


In general, digital angiographic equipment is used to aid the performance of the ultrasound catheter treatment procedure. Continuous invasive pressure monitoring and ECG-monitoring can be used for obtaining baseline hemodynamic parameters, including heart rate, right atrial, right ventricular, and pulmonary artery pressures, as well as the mixed-venous oxygen saturation from the pulmonary artery. A systemic arterial blood pressure and a systemic oxygen saturation can also be measured if an arterial line is in place. Otherwise, the systemic cuff blood pressure is measured and the oxygen saturation is obtained by pulse oximetry. In one embodiment, a blood pressure sensor is integrated into the ultrasound catheter.


In some embodiments, a feedback control loop configured to monitor the baseline hemodynamic parameters and/or mixed-venous oxygen saturation can be integrated into the control system 100. The output power of the energy source can then be adjusted according to the readings. A physician can override the closed or open loop system if so desired.


In some embodiments, an unilateral filling defect in one main or proximal lower lobe pulmonary artery by contrast-enhanced chest CT indicates that only one ultrasound catheter is to be placed into the pulmonary artery. In case of bilateral filling defect is detected in both main or proximal lower lobe pulmonary arteries by contrast-enhancing chest CT, two ultrasound catheters may be placed.


As noted above, in some embodiments, femoral venous access may be used for placing the ultrasound catheter in the pulmonary arteries. For example, a 6F introducer sheath is inserted in the common femoral vein. An exchange-length 0.035-inch (0.089-cm) angled guidewire, for example the Terumo soft wire, may be used for probing the embolic occlusion under fluoroscopy. A 5F standard angiographic catheter, such as a multipurpose catheter or pigtail catheter or any other pulmonary angiographic catheter may be used with small manual contrast injections for localizing the embolic occlusion and for positioning the catheter such that the energy delivery section 18 of the ultrasound catheter spans the thrombus. If the distal extent of the embolus is not visible angiographically or if it is difficult to probe the embolic occlusion, a 4F Terumo glide catheter may be used for obtaining very small selective contrast injections beyond the presumed thrombotic occlusion after transiently removing the 0.035 wire. After the wire is successfully placed beyond the thrombotic occlusion in a lower lobe segmental branch, the angiographic catheter is exchanged for the ultrasound catheter.


Finally, in embodiments wherein the ultrasound catheter including elongate inner core with ultrasound catheter (as shown in FIGS. 1-11) is used, the 0.035-inch (0.089-cm) guidewire can be removed and the elongate inner core with ultrasound radiating member(s) 40 is inserted into the ultrasound catheter. The therapeutic compound can be introduced through the at least one fluid delivery lumen 30 and out of the fluid delivery port(s) 58 to the treatment site.


After about 12 to about 15 hours of drug infusion, the rt-PA infusion can be replaced with heparinized saline infusion (about 1 μg/ml) at an infusion rate of 5 ml/hr. Sometime between about 16 and about 24 hours after the start of the rt-PA infusion, follow-up hemodynamic measurements (heart rate, systemic arterial pressure, right atrial, right ventricular and pulmonary artery pressures, mixed venous and pulse oximetric oxygen saturations, cardiac output, pulmonary vascular resistance) and controlled removal of the ultrasound catheter can be performed. The decision on the exact duration of the ultrasound-assisted thrombolysis infusion is at the discretion of the physician, but in one embodiment it is recommended to continue the treatment for 15 hours (or until 20 mg of rt-PA has been delivered) if well tolerated by the patient.


In certain embodiments, it can be beneficial to keep the catheter centered in the pulmonary artery during the treatment process. For example, centering the ultrasound radiating member 40 in the pulmonary artery may improve the uniform exposure at the treatment site. In some embodiments, the ultrasound catheter 10 also includes a centering mechanism for keeping the catheter centered during the treatment. In some embodiments, the centering mechanism of the catheter 10 can be provided with one or more balloons disposed around the catheter 10 toward the distal region 15.


As described above, in some embodiments, the ultrasound assembly 42 comprises a plurality of ultrasound radiating members 40 that are divided into one or more groups. For example, FIGS. 5 and 6 are schematic wiring diagrams illustrating one technique for connecting five groups of ultrasound radiating members 40 to form the ultrasound assembly 42. As illustrated in FIG. 5, the ultrasound assembly 42 comprises five groups G1, G2, G3, G4, and G5 of ultrasound radiating members 40 that are electrically connected to each other. The five groups are also electrically connected to the control system 100. In some embodiments, two, three, or four or more than five groups of ultrasound radiating member 40 may be electrically connected to each other and the control system 100. Each group (G1-GS) may comprise one or more individual ultrasound elements. For example, in one embodiment, each group comprises five or less (i.e., one, two, three, four, or five) ultrasound radiating members 40. In other embodiments, more than 5 ultrasound elements can be provided in each group. Modified embodiments may also include different numbers of elements within each group.


In the embodiment of FIG. 6, each group G1-G5 comprises a plurality of ultrasound radiating members 40. Each of the ultrasound radiating members 40 is electrically connected to the common wire 108 and to the lead wire 110 via one of two positive contact wires 112. Thus, when wired as illustrated, a constant voltage difference will be applied to each ultrasound radiating member 40 in the group. Although the group illustrated in FIG. 6 comprises twelve ultrasound radiating members 40, one of ordinary skill in the art will recognize that more or fewer ultrasound radiating members 40 can be included in the group. Likewise, more or fewer than five groups can be included within the ultrasound assembly 42 illustrated in FIG. 5.


The wiring arrangement described above can be modified to allow each group G1, G2, G3, G4, G5 to be independently powered. Specifically, by providing a separate power source within the control system 100 for each group, each group can be individually turned on or off, or can be driven with an individualized power. This provides the advantage of allowing the delivery of ultrasonic energy to be “turned off” in regions of the treatment site where treatment is complete, thus preventing deleterious or unnecessary ultrasonic energy to be applied to the patient.


The embodiments described above, and illustrated in FIGS. 5 through 7, illustrate a plurality of ultrasound radiating members grouped spatially. That is, in such embodiments, all of the ultrasound radiating members within a certain group are positioned adjacent to each other, such that when a single group is activated, ultrasonic energy is delivered at a specific length of the ultrasound assembly. However, in modified embodiments, the ultrasound radiating members of a certain group can be interdigitated with respect to ultrasound radiating members of a different group.


Method for Assembling a Catheter with a Temperature Sensor


As discussed above, the configuration of the temperature sensor 20 in the exterior tubular body 12 can provide for ease of assembly and manufacturability. In one aspect, the disclosure resides in a method of manufacturing a catheter comprising a flexible circuit and/or a ribbon thermocouple according to any of the embodiments described herein. In a particular embodiment of the disclosure, the flexible circuit is configured to form a thermocouple. In a particular embodiment of the disclosure, the thermocouple ribbon is configured to form a thermocouple. FIG. 13 illustrates a flow-chart of an example method for assembling a catheter with a flex circuit thermocouple and/or thermocouple ribbon.


The method for assembling a catheter with flex circuit thermocouple and/or thermocouple ribbon can first include block 410 which describes first inserting the interior tubular body 13 into the exterior tubular body 12. In some embodiments, the interior tubular body 13 can be inserted into the exterior tubular body 12 such that the outside surface of the interior tubular body 13 contacts the inside surface of the exterior tubular body 12. This can form an asymmetrical space within the exterior tubular body 12 to accommodate a temperature sensor 20.


Next, the method can include block 420 which describes inserting the flexcircuit temperature sensor 20 or and/or thermocouple ribbon 500, 600 through the first barb inlet 69 of the distal hub 65. As described above, the temperature sensor 20 can be the flexcircuit 220 of FIGS. 2A and 2B or flexcircuit 320 of FIGS. 12A-12B or ribbon thermocouple 500, 660 of FIGS. 2D-2I.


Once inserted, the temperature sensor 20 can be attached to the proximal and distal ends of the interior tubular body 13 as discussed in block 430 and block 440. The attachment of the temperature sensor 20 to the interior tubular body 13 can be done using an adhesive or a heat shrink.


At block 450, the remaining components of the catheter 10 are assembled. For example, in the catheter 10 described above, FIG. 1E illustrates an exploded view of the various components of the catheter 10 and the connections between each of the components.


Once the catheter 10 has been assembled, the method can include block 460 which describes attaching the fluid lines (e.g. fluid line 91 and cooling fluid line 92) to the catheter. As shown above, the fluid line 91 can be attached to the second barb inlet 75 while the cooling fluid line 92 is attached to the barb inlet 63.


To attach the temperature sensor 20 to an electrical source, block 470 describes connecting the temperature sensor 20 to a cable assembly. As illustrated in FIG. 1E, the cable 45 can attach to the temperature sensor 20 through first barb inlet 69. The distal end of the cable 45 can then attach to a control system 100. The various methods and techniques described above provide a number of ways to carry out the disclosure. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods may be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.


The disclosure includes the following additional embodiments:


Embodiment 1. An ultrasound catheter comprising:


a first tubular body having a first longitudinal axis extending centrally through the tubular body, the first tubular body including at least one delivery port extending through a wall of the first tubular body;


a second tubular body having a second longitudinal axis extending centrally through the second tubular body, the first and second longitudinal axes being displaced from each other such that an asymmetrical longitudinally extending gap is formed between an outer surface of the second tubular body and an interior surface of the first tubular body;


a flexible circuit forming a thermocouple extending longitudinally within the gap between the first tubular body and the second tubular body; and


an inner core positioned within the second tubular body, the inner core comprising at least one ultrasound element.


Embodiment 2: The ultrasound catheter of Embodiment 1, wherein the flexible circuit positioned in the widest portion of the asymmetrical gap.


Embodiment 3: The ultrasound catheter of any one of Embodiments 1-2, wherein the flexible circuit extends along the length of the first tubular body.


Embodiment 4: The ultrasound catheter of any one of Embodiments 1-3, wherein the flexible circuit is adjacent to an outer surface of the second tubular body.


Embodiment 5: The ultrasound catheter of any one of Embodiments 1-4, wherein the ultrasound catheter comprises a first fluid injection port in fluid communication with the gap.


Embodiment 6: The ultrasound catheter of any one of Embodiments 1-5, wherein the apparatus further comprises a second fluid injection port in fluid communication with an interior of the second tubular body.


Embodiment 7: The ultrasound catheter of any one of Embodiments 1-6, wherein the flexible circuit is configured to measure temperature at different points along the length of ultrasound catheter.


Embodiment 8: The ultrasound catheter of any one of Embodiments 1-7, wherein the inner core comprises a plurality of ultrasound radiating members extending along a length of the ultrasound catheter.


Embodiment 9: The ultrasound catheter of Embodiment 8, wherein the flexible circuit comprises a plurality of joints between traces of dissimilar materials.


Embodiment 10: The ultrasound catheter of Embodiment 9, wherein the plurality of joints between traces of dissimilar materials extend along the length of the ultrasound catheter in which the plurality of ultrasound radiating members is positioned.


Embodiment 11: The ultrasound catheter of Embodiment 10, wherein the joints between traces of dissimilar materials are formed by a plurality traces of a first material connected to a single trace of second dissimilar material.


Embodiment 12: The ultrasound catheter of Embodiment 1, wherein the flexible circuit comprises a plurality of traces formed on the flexible circuit separated by insulating material, the plurality of traces comprising at least two traces of a first material connected to a single trace of second dissimilar material at different points along a length of the flexible circuit.


Embodiment 13: A method of manufacturing a catheter comprising:

    • inserting an inner tubular body into an outer tubular body; and
    • placing a flexible circuit between the outer and inner tubular body, wherein the temperature sensor is adjacent to an outer surface of the inner tubular body such that the inner tubular body does not extend along the same longitudinal axis a the outer tubular body.


Embodiment 14: The method of manufacturing of Embodiment 13, wherein the flexible circuit is configured to form a thermocouple.


Embodiment 15: The method of manufacturing of Embodiment 13, further comprising: forming an inner core, wherein the inner core is configured to be insertable into the inner tubular body.


Embodiment 16: The method of manufacturing of Embodiment 13, wherein inserting the elongate fluid delivery body and inserting the temperature sensor forms an asymmetrical cross-section in the catheter.


Embodiment 17: An ultrasound catheter comprising:

    • an elongate inner tubular body;
    • an elongate outer tubular;
      • wherein the elongate inner tubular body is positioned within the elongate outer tubular body to form an asymmetrical gap between an outer surface of the inner tubular body and an interior surface of the elongate outer tubular body to form a fluid delivery lumen, and
    • a temperature sensor extending along the outer surface of the inner tubular body within the gap; and
    • an inner core positioned within the inner tubular body and comprising at least one ultrasound element.


Embodiment 18: The ultrasound catheter of Embodiment 17, wherein the temperature sensor is formed by a flexible circuit.


Embodiment 19: An ultrasound catheter of Embodiment 18, wherein the temperature sensor is located in the widest portion of the asymmetrical gap.


Embodiment 20: A flexible circuit for a catheter, the flex circuit comprising a plurality of traces formed on the flexible circuit separated by insulating material, the plurality of traces comprising at least two traces of a first material connected to a single trace of second dissimilar material at different points along a length of the flexible circuit.


Embodiment 22: The flexible circuit of Embodiment 20, wherein the second dissimilar material is Constantan and the first material is copper.


Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments disclosed herein. Similarly, the various features and steps discussed above, as well as other known equivalents for each such feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Additionally, the methods which is described and illustrated herein is not limited to the exact sequence of acts described, nor is it necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the embodiments of the invention.


Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, the invention is not intended to be limited by the specific disclosures of embodiments herein.

Claims
  • 1. A method of manufacturing a catheter comprising: inserting an inner tubular body into an outer tubular body;placing a temperature sensor between the outer and inner tubular body, wherein the temperature sensor is adjacent to an outer surface of the inner tubular body such that the inner tubular body does not extend along the same longitudinal axis as the outer tubular body; andwherein the inner tubular body is asymmetrical and includes a plurality of indentations along the interior surface of the inner tubular body.
  • 2. The method of manufacturing of claim 1, wherein the temperature sensor is configured to form a thermocouple.
  • 3. The method of manufacturing of claim 1, further comprising: forming an inner core, wherein the inner core is configured to be insertable into the inner tubular body.
  • 4. The method of manufacturing of claim 3, wherein the inner core comprises at least one ultrasound element.
  • 5. The method of manufacturing of claim 1, wherein inserting an inner tubular body into an outer tubular body and placing a temperature sensor between the outer and inner tubular body forms an asymmetrical cross-section in the catheter.
  • 6. The method of manufacturing of claim 1, wherein the temperature sensor comprises a flexcircuit.
  • 7. The method of manufacturing of claim 1, wherein an asymmetrical longitudinally extending gap is formed between an outer surface of the inner tubular body and an interior surface of the outer tubular body.
  • 8. The method of manufacturing of claim 7, wherein the temperature sensor is positioned in a widest portion of the asymmetrical gap.
  • 9. The method of manufacturing of claim 1, wherein the temperature sensor extends along a length of the outer tubular body.
  • 10. The method of manufacturing of claim 1, wherein the temperature sensor comprises a flexible circuit that comprises a plurality of joints between traces of dissimilar materials.
  • 11. A method of manufacturing a catheter comprising: inserting an inner tubular body into an outer tubular body; andplacing a temperature sensor between the outer and inner tubular body, wherein the temperature sensor is adjacent to an outer surface of the inner tubular body such that the inner tubular body does not extend along the same longitudinal axis as the outer tubular body;wherein the temperature sensor comprises a plurality of filament pairs wherein each of the filaments is insulated; anda plurality of thermocouples wherein each of the plurality of thermocouples are formed between each of the plurality of filament pairs.
  • 12. A method of manufacturing a catheter comprising: inserting an inner tubular body into an outer tubular body;
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/178,398 filed Jun. 9, 2016, now U.S. Pat. No. 10,495,520; which claims the benefit of priority to U.S. Provisional Application No. 62/173,863, filed Jun. 10, 2015, the entirety of which are herein incorporated by reference.

US Referenced Citations (965)
Number Name Date Kind
2961382 Singher et al. Nov 1960 A
3352303 Delaney Nov 1967 A
3430625 McLeod, Jr. Mar 1969 A
3433226 Boyd Mar 1969 A
3437851 Cady Apr 1969 A
3443226 Knight May 1969 A
3565062 Kuris Feb 1971 A
3635213 Lahay Jan 1972 A
3794910 Ninked et al. Feb 1974 A
3827115 Bom Aug 1974 A
3861391 Antonevich et al. Jan 1975 A
3902083 Zoltan Aug 1975 A
D238905 Sokol et al. Feb 1976 S
3938502 Bom Feb 1976 A
3941122 Jones Mar 1976 A
3976987 Anger Aug 1976 A
4006743 Kowarski Feb 1977 A
4027659 Slingluff Jun 1977 A
4040414 Suroff Aug 1977 A
D247251 Napoli Feb 1978 S
4192294 Vasilevsky et al. Mar 1980 A
4265251 Tickner May 1981 A
4309989 Fahim Jan 1982 A
4312361 Nicholson et al. Jan 1982 A
4319580 Colley et al. Mar 1982 A
D264128 Barnes et al. Apr 1982 S
4354502 Colley et al. Oct 1982 A
4381004 Babb Apr 1983 A
4457748 Lallin et al. Jul 1984 A
4466442 Hilmann et al. Aug 1984 A
4512762 Spears Apr 1985 A
4531943 Van Tassel et al. Jul 1985 A
4549533 Cain et al. Oct 1985 A
4557723 Sibalis Dec 1985 A
4573470 Samson et al. Mar 1986 A
4582067 Silverstein et al. Apr 1986 A
4587975 Salo et al. May 1986 A
4605399 Weston et al. Aug 1986 A
4639735 Yamamoto et al. Jan 1987 A
4640689 Slibalis Feb 1987 A
4646754 Seale Mar 1987 A
4657543 Langer et al. Apr 1987 A
4657756 Rasor et al. Apr 1987 A
4682596 Bales et al. Jul 1987 A
4692139 Stiles Sep 1987 A
4697595 Breyer et al. Oct 1987 A
4698058 Greenfeld et al. Oct 1987 A
4699150 Kawabuchi et al. Oct 1987 A
4702732 Powers et al. Oct 1987 A
4708716 Sibalis Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4710192 Liotta et al. Dec 1987 A
4717379 Ekholmer Jan 1988 A
4729384 Bazenet Mar 1988 A
4739768 Engelson Apr 1988 A
D296240 Albright et al. Jun 1988 S
4750902 Wuchinich et al. Jun 1988 A
4754752 Ginsburg et al. Jul 1988 A
4762915 Kung et al. Aug 1988 A
4767402 Kost et al. Aug 1988 A
4769017 Fath et al. Sep 1988 A
4770185 Silverstein et al. Sep 1988 A
4772594 Hashimoto et al. Sep 1988 A
4774958 Feinstein Oct 1988 A
4780212 Kost et al. Oct 1988 A
4781677 Wilcox Nov 1988 A
4787883 Kroyer Nov 1988 A
4795439 Guest Jan 1989 A
4797285 Barenholz et al. Jan 1989 A
4808153 Parisi Feb 1989 A
4820260 Hayden Apr 1989 A
4821740 Tachibana et al. Apr 1989 A
4841977 Griffith et al. Jun 1989 A
4844882 Widder et al. Jul 1989 A
4855064 Schlein Aug 1989 A
4870953 Don Micheal et al. Oct 1989 A
4877031 Conway et al. Oct 1989 A
4883457 Sibalis Nov 1989 A
4900540 Ryan et al. Feb 1990 A
4917088 Crittenden Apr 1990 A
4917102 Miller et al. Apr 1990 A
4920954 Alliger et al. May 1990 A
4921478 Solano et al. May 1990 A
4924863 Sterzer May 1990 A
4933843 Scheller et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4947852 Nassi et al. Aug 1990 A
4948587 Kost et al. Aug 1990 A
4951677 Crowley et al. Aug 1990 A
4953565 Tachibana et al. Sep 1990 A
4955863 Walker et al. Sep 1990 A
4960109 Lele Oct 1990 A
4969470 Mohl et al. Nov 1990 A
4971991 Umemura et al. Nov 1990 A
4992257 Bonnett et al. Feb 1991 A
4995865 Gahara et al. Feb 1991 A
5007438 Tachibana et al. Apr 1991 A
5007898 Rosenbluth et al. Apr 1991 A
5021044 Sharkawy Jun 1991 A
5026387 Thomas Jun 1991 A
5040537 Katakura Aug 1991 A
5053008 Bajaj Oct 1991 A
5053044 Mueller et al. Oct 1991 A
5058570 Idemoto et al. Oct 1991 A
5059851 Corl et al. Oct 1991 A
5069664 Guess et al. Dec 1991 A
5076276 Sakurai et al. Dec 1991 A
5081993 Kitney et al. Jan 1992 A
5085662 Willard Feb 1992 A
5088499 Unger Feb 1992 A
5095910 Powers Mar 1992 A
5108369 Ganguly et al. Apr 1992 A
5115805 Bommannan et al. May 1992 A
5117831 Jang et al. Jun 1992 A
5121749 Nassi et al. Jun 1992 A
5125410 Misono et al. Jun 1992 A
5129883 Black Jul 1992 A
5149319 Unger Sep 1992 A
5150705 Stinson Sep 1992 A
D330424 Davis et al. Oct 1992 S
5156050 Schmid Oct 1992 A
5158071 Umemura et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5163436 Saitoh et al. Nov 1992 A
5178620 Eggers et al. Jan 1993 A
5181920 Mueller et al. Jan 1993 A
5185071 Serwer et al. Feb 1993 A
5190766 Ishihara Mar 1993 A
5195520 Schlief et al. Mar 1993 A
5197946 Tachibana Mar 1993 A
5203337 Feldman Apr 1993 A
5207214 Romano May 1993 A
5209720 Unger May 1993 A
5215680 D'arrigo Jun 1993 A
5216130 Line et al. Jun 1993 A
5226421 Frisbie et al. Jul 1993 A
5250034 Appling et al. Oct 1993 A
5261291 Schoch et al. Nov 1993 A
5267954 Nita Dec 1993 A
5267985 Shimada et al. Dec 1993 A
5269291 Carter Dec 1993 A
5269297 Weng et al. Dec 1993 A
5271406 Ganguly et al. Dec 1993 A
5277913 Thompson et al. Jan 1994 A
5279543 Glikfeld et al. Jan 1994 A
5279546 Mische et al. Jan 1994 A
5282785 Shapland et al. Feb 1994 A
5286254 Shapland et al. Feb 1994 A
5289831 Bosley Mar 1994 A
5291887 Stanley et al. Mar 1994 A
5295484 Marcus et al. Mar 1994 A
5295958 Shturman Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5307816 Hashimoto et al. May 1994 A
5312328 Nita et al. May 1994 A
5313949 Yock May 1994 A
5315998 Tachibana et al. May 1994 A
5318014 Carter Jun 1994 A
5323769 Bommannan et al. Jun 1994 A
5324225 Satoh et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5326342 Pflueger et al. Jul 1994 A
5327891 Rammler Jul 1994 A
5328470 Nabel et al. Jul 1994 A
5342292 Nita et al. Aug 1994 A
5342608 Moriya et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5344435 Turner et al. Sep 1994 A
5345940 Seward et al. Sep 1994 A
5348481 Ortiz Sep 1994 A
5351693 Taimisto et al. Oct 1994 A
5353798 Sieben Oct 1994 A
5354279 Hoefung Oct 1994 A
5362309 Carter Nov 1994 A
5363853 Lieber et al. Nov 1994 A
5364344 Beattie et al. Nov 1994 A
5368036 Tanaka et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368558 Nita Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5372138 Crowley et al. Dec 1994 A
5378230 Mahurkar Jan 1995 A
5380273 Dubrul et al. Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5390678 Gesswein et al. Feb 1995 A
5397293 Alliger et al. Mar 1995 A
5397301 Pflueger et al. Mar 1995 A
5399158 Lauer et al. Mar 1995 A
5401237 Tachibana et al. Mar 1995 A
5403323 Smith Apr 1995 A
5405322 Lennox et al. Apr 1995 A
5409458 Khairkhahan et al. Apr 1995 A
5415636 Forman May 1995 A
5419763 Hildabrand May 1995 A
5421338 Crowley et al. Jun 1995 A
5423797 Adrian et al. Jun 1995 A
5431663 Carter Jul 1995 A
5440914 Tachibana et al. Aug 1995 A
5445155 Sieben Aug 1995 A
5447509 Mills et al. Sep 1995 A
5447510 Jensen Sep 1995 A
5453575 O'donnell et al. Sep 1995 A
5454782 Perkins Oct 1995 A
5454795 Samson Oct 1995 A
5456259 Barlow et al. Oct 1995 A
5456726 Kawabata et al. Oct 1995 A
5458568 Racchini et al. Oct 1995 A
5461708 Kahn Oct 1995 A
5462523 Samson et al. Oct 1995 A
5465726 Dickinson et al. Nov 1995 A
5474530 Passafaro et al. Dec 1995 A
5474531 Carter Dec 1995 A
5489279 Meserol Feb 1996 A
5496294 Hergenrother et al. Mar 1996 A
5498236 Dubrul et al. Mar 1996 A
5498238 Shapland et al. Mar 1996 A
5509896 Carter Apr 1996 A
5514092 Forman et al. May 1996 A
5520189 Malinowski et al. May 1996 A
5523058 Umemura et al. Jun 1996 A
5524624 Tepper et al. Jun 1996 A
5531715 Engelson et al. Jul 1996 A
5533986 Mottola et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5542935 Unger et al. Aug 1996 A
5558092 Unger et al. Sep 1996 A
5558642 Schweich, Jr. et al. Sep 1996 A
5560362 Sliwa et al. Oct 1996 A
5562608 Sekins et al. Oct 1996 A
5567687 Magda et al. Oct 1996 A
5569197 Helmus et al. Oct 1996 A
5569198 Racchini Oct 1996 A
5580575 Unger et al. Dec 1996 A
5582586 Tachibana et al. Dec 1996 A
5585112 Unger et al. Dec 1996 A
5586982 Abela Dec 1996 A
5588432 Crowley Dec 1996 A
5588962 Nicholas et al. Dec 1996 A
5594136 Sessler et al. Jan 1997 A
5599326 Carter Feb 1997 A
5599923 Sessler et al. Feb 1997 A
5603327 Eberle et al. Feb 1997 A
5603694 Brown et al. Feb 1997 A
5606974 Castellano et al. Mar 1997 A
5609574 Kaplan et al. Mar 1997 A
5616342 Lyons Apr 1997 A
5617851 Lipkovker Apr 1997 A
5618275 Bock Apr 1997 A
5620409 Venuto et al. Apr 1997 A
5620479 Diederich Apr 1997 A
5624382 Oppelt et al. Apr 1997 A
5628728 Tachibana et al. May 1997 A
5628730 Shapland et al. May 1997 A
5630837 Crowley May 1997 A
5632970 Sessler et al. May 1997 A
D380543 Piontek et al. Jul 1997 S
5648098 Porter Jul 1997 A
5656016 Ogden Aug 1997 A
5660180 Malinowski et al. Aug 1997 A
5660909 Tachibana et al. Aug 1997 A
5663327 Tambo et al. Sep 1997 A
5665076 Roth et al. Sep 1997 A
5681296 Ishida Oct 1997 A
5688364 Sato Nov 1997 A
5694936 Fujimoto et al. Dec 1997 A
5695460 Siegel et al. Dec 1997 A
5697897 Buchholtz et al. Dec 1997 A
5707608 Liu Jan 1998 A
5713831 Olsson Feb 1998 A
5713848 Dubrul et al. Feb 1998 A
5715825 Crowley Feb 1998 A
5718921 Mathiowitz et al. Feb 1998 A
5720710 Tachibana et al. Feb 1998 A
5724976 Mine et al. Mar 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5733315 Burdette et al. Mar 1998 A
5733572 Unger et al. Mar 1998 A
5735811 Brisken Apr 1998 A
5752930 Rise et al. May 1998 A
5766902 Craig et al. Jun 1998 A
5770222 Unger et al. Jun 1998 A
5772627 Acosta et al. Jun 1998 A
5772632 Forman Jun 1998 A
5775338 Hastings Jul 1998 A
5776429 Unger et al. Jul 1998 A
5779644 Eberle et al. Jul 1998 A
5779673 Roth et al. Jul 1998 A
5782811 Samson et al. Jul 1998 A
5800421 Lemelson Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5817021 Reichenberger Oct 1998 A
5817048 Lawandy Oct 1998 A
5823962 Schaetzle et al. Oct 1998 A
5824005 Motamed et al. Oct 1998 A
5827203 Nita Oct 1998 A
5827313 Ream Oct 1998 A
5827529 Ono et al. Oct 1998 A
5834880 Venkataramani et al. Nov 1998 A
5836440 Mindich Nov 1998 A
5836896 Rosenschein Nov 1998 A
5836940 Gregory Nov 1998 A
5840031 Crowley Nov 1998 A
5842994 Fenhoff et al. Dec 1998 A
5843109 Mehta et al. Dec 1998 A
5846218 Brisken et al. Dec 1998 A
5846517 Unger Dec 1998 A
5849727 Porter et al. Dec 1998 A
5876345 Eaton et al. Mar 1999 A
5876989 Berg et al. Mar 1999 A
5895356 Andrus et al. Apr 1999 A
5895358 Becker et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5897503 Lyon et al. Apr 1999 A
5908445 Whayne et al. Jun 1999 A
5916192 Nita et al. Jun 1999 A
5922687 Mann et al. Jul 1999 A
5925016 Chornenky et al. Jul 1999 A
5928186 Homsma et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5934284 Plaia et al. Aug 1999 A
5935124 Klumb et al. Aug 1999 A
5938595 Glass et al. Aug 1999 A
5941068 Brown et al. Aug 1999 A
5941868 Kaplan et al. Aug 1999 A
5941896 Kerr Aug 1999 A
5951494 Wang et al. Sep 1999 A
5957851 Hossack Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream Sep 1999 A
5971949 Levin et al. Oct 1999 A
5976120 Chow et al. Nov 1999 A
5984882 Rosenschein et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
6001069 Tachibana et al. Dec 1999 A
6004069 Sudbury Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6007514 Nita Dec 1999 A
6024703 Zanelli et al. Feb 2000 A
6024718 Chen et al. Feb 2000 A
6027515 Cimino Feb 2000 A
6030374 McDaniel Feb 2000 A
6033397 Laufer et al. Mar 2000 A
6044845 Lewis Apr 2000 A
6053868 Geistert et al. Apr 2000 A
6059731 Seward et al. May 2000 A
6063069 Cragg et al. May 2000 A
6066123 Li et al. May 2000 A
6068857 Weitschies et al. May 2000 A
6078830 Levin et al. Jun 2000 A
D427574 Sawada et al. Jul 2000 S
6086573 Siegel et al. Jul 2000 A
6088613 Unger Jul 2000 A
6089573 Udagawa Jul 2000 A
6096000 Tachibana et al. Aug 2000 A
6096070 Ragheb et al. Aug 2000 A
6110098 Renirie et al. Aug 2000 A
6110314 Nix et al. Aug 2000 A
6113546 Suorsa et al. Sep 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113570 Siegel et al. Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6117858 Porter et al. Sep 2000 A
6120454 Suorsa et al. Sep 2000 A
RE36939 Tachibana et al. Oct 2000 E
6135971 Hutchinson et al. Oct 2000 A
6135976 Tachibana et al. Oct 2000 A
6136792 Henderson Oct 2000 A
6143013 Samson et al. Nov 2000 A
6144869 Bemer et al. Nov 2000 A
6149596 Bancroft Nov 2000 A
6149599 Schlesinger et al. Nov 2000 A
6176842 Tachibana et al. Jan 2001 B1
6190315 Kost et al. Feb 2001 B1
6190355 Hastings Feb 2001 B1
6196973 Lazenby et al. Mar 2001 B1
6206831 Suorsa et al. Mar 2001 B1
6210356 Anderson et al. Apr 2001 B1
6210393 Brisken Apr 2001 B1
6221038 Brisken Apr 2001 B1
6228046 Brisken May 2001 B1
6231516 Keilman et al. May 2001 B1
6235024 Tu May 2001 B1
6238347 Nix et al. May 2001 B1
6241703 Levin et al. Jun 2001 B1
6245747 Porter et al. Jun 2001 B1
6261246 Pantages et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277077 Brisken et al. Aug 2001 B1
6283920 Eberle et al. Sep 2001 B1
6287271 Dubrul et al. Sep 2001 B1
6295990 Lewis et al. Oct 2001 B1
6296610 Schneider et al. Oct 2001 B1
6296619 Brisken et al. Oct 2001 B1
6298264 Zhong et al. Oct 2001 B1
6299597 Buscemi et al. Oct 2001 B1
6309370 Haim et al. Oct 2001 B1
6312402 Hansmann Nov 2001 B1
6312425 Simpson et al. Nov 2001 B1
6319220 Bylsma Nov 2001 B1
6322513 Schregel Nov 2001 B1
6346098 Yock et al. Feb 2002 B1
6356776 Berner et al. Mar 2002 B1
6361500 Masters Mar 2002 B1
6361554 Brisken Mar 2002 B1
6366719 Heath et al. Apr 2002 B1
6368315 Gillis et al. Apr 2002 B1
6372498 Newman et al. Apr 2002 B2
6379320 Lafon et al. Apr 2002 B1
6387035 Jung et al. May 2002 B1
6387052 Quinn et al. May 2002 B1
6391042 Cimino May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6394997 Lemelson May 2002 B1
6398772 Bond et al. Jun 2002 B1
6398792 O'Connor Jun 2002 B1
6416740 Unger Jul 2002 B1
6423026 Gesswein et al. Jul 2002 B1
6425853 Edwards Jul 2002 B1
6433464 Jones Aug 2002 B2
6435189 Lewis et al. Aug 2002 B1
6437487 Mohr et al. Aug 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6456863 Levin et al. Sep 2002 B1
6461296 Desai Oct 2002 B1
6461314 Pant et al. Oct 2002 B1
6461383 Gesswein et al. Oct 2002 B1
6461586 Unger Oct 2002 B1
6464680 Brisken et al. Oct 2002 B1
6471683 Drasler et al. Oct 2002 B2
6478765 Siegel et al. Nov 2002 B2
6485430 Quinn et al. Nov 2002 B1
6485853 Pettit et al. Nov 2002 B1
6493731 Jones et al. Dec 2002 B1
6494891 Cornish et al. Dec 2002 B1
6503202 Hossack et al. Jan 2003 B1
6506584 Chandler et al. Jan 2003 B1
6508775 McKenzie et al. Jan 2003 B2
6508816 Shadduck Jan 2003 B2
6511478 Burnside et al. Jan 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6524271 Brisken et al. Feb 2003 B2
6524300 Meglin Feb 2003 B2
6527759 Tachibana et al. Mar 2003 B1
6527761 Soltesz et al. Mar 2003 B1
6537224 Mauchamp et al. Mar 2003 B2
6537306 Burdette et al. Mar 2003 B1
6542767 McNichols et al. Apr 2003 B1
6544259 Tsaliovich Apr 2003 B1
6548047 Unger Apr 2003 B1
6551337 Rabiner et al. Apr 2003 B1
6558366 Drasler et al. May 2003 B1
6560837 Hodjat et al. May 2003 B1
6561998 Roth et al. May 2003 B1
6562021 Derbin et al. May 2003 B1
6565552 Barbut May 2003 B1
6575922 Fearnside et al. Jun 2003 B1
6575956 Brisken et al. Jun 2003 B1
6579277 Rabiner et al. Jun 2003 B1
6579279 Rabiner et al. Jun 2003 B1
6582392 Bennett et al. Jun 2003 B1
6585678 Tachibana et al. Jul 2003 B1
6585763 Keilman et al. Jul 2003 B1
6589182 Loftman et al. Jul 2003 B1
6589253 Cornish et al. Jul 2003 B1
6594514 Bemer et al. Jul 2003 B2
6599288 Maguire et al. Jul 2003 B2
6605084 Acker et al. Aug 2003 B2
6607502 Maguire et al. Aug 2003 B1
6623444 Babaev Sep 2003 B2
6635017 Moehring et al. Oct 2003 B1
6635046 Barbut Oct 2003 B1
6645150 Angelsen et al. Nov 2003 B2
6647755 Rabiner et al. Nov 2003 B2
6652536 Mathews et al. Nov 2003 B2
6652547 Rabiner et al. Nov 2003 B2
6652581 Ding Nov 2003 B1
6660013 Rabiner et al. Dec 2003 B2
6663613 Evans et al. Dec 2003 B1
6676626 Bennett et al. Jan 2004 B1
6680301 Berg et al. Jan 2004 B2
6682502 Bond et al. Jan 2004 B2
6689086 Nita et al. Feb 2004 B1
6695781 Rabiner et al. Feb 2004 B2
6695782 Ranucci et al. Feb 2004 B2
6695785 Brisken et al. Feb 2004 B2
6699269 Khanna Mar 2004 B2
6711953 Hayashi et al. Mar 2004 B2
6723063 Zhang et al. Apr 2004 B1
6723064 Babaev Apr 2004 B2
6726698 Cimino Apr 2004 B2
6730048 Hare et al. May 2004 B1
6733450 Alexandrov et al. May 2004 B1
6733451 Rabiner et al. May 2004 B2
6733515 Edwards et al. May 2004 B1
6740040 Mandrusov et al. May 2004 B1
6758857 Cioanta et al. Jul 2004 B2
6764860 Lee Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6794369 Newman et al. Sep 2004 B2
6796992 Barbut Sep 2004 B2
6797293 Shin et al. Sep 2004 B2
6824515 Suorsa et al. Nov 2004 B2
6824575 Otomo et al. Nov 2004 B1
6830577 Nash et al. Dec 2004 B2
6849062 Kantor Feb 2005 B2
6850790 Berner et al. Feb 2005 B2
6855123 Nita Feb 2005 B2
6866670 Rabiner et al. Mar 2005 B2
6896659 Conston et al. May 2005 B2
6905505 Nash et al. Jun 2005 B2
6908448 Redding Jun 2005 B2
6913581 Corl et al. Jul 2005 B2
6921371 Wilson Jul 2005 B2
6929632 Nita et al. Aug 2005 B2
6929633 Evans et al. Aug 2005 B2
6942620 Nita et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6945937 Culp et al. Sep 2005 B2
6958040 Oliver et al. Oct 2005 B2
6958059 Zadno-Azizi Oct 2005 B2
6979293 Hansmann et al. Dec 2005 B2
6985771 Fischell et al. Jan 2006 B2
7025425 Kovatchev et al. Apr 2006 B2
7077820 Kadziauskas et al. Jul 2006 B1
D526655 McDougall et al. Aug 2006 S
7084118 Armstrong et al. Aug 2006 B2
7089063 Lesh et al. Aug 2006 B2
7137963 Nita et al. Nov 2006 B2
7141044 Gentsler Nov 2006 B2
D534654 Hayamizu Jan 2007 S
7166098 Steward et al. Jan 2007 B1
7174199 Berner et al. Feb 2007 B2
7178109 Hewson et al. Feb 2007 B2
7186246 Bennett et al. Mar 2007 B2
7220233 Nita et al. May 2007 B2
7220239 Wilson et al. May 2007 B2
7235063 D'Antonio et al. Jun 2007 B2
7264597 Cathignol Sep 2007 B2
D555165 Myers et al. Nov 2007 S
7300414 Holland et al. Nov 2007 B1
7308303 Whitehurst et al. Dec 2007 B2
7309334 von Hoffmann Dec 2007 B2
7335180 Nita et al. Feb 2008 B2
D564094 Hayashi Mar 2008 S
D564661 Hayashi Mar 2008 S
7341569 Soltani et al. Mar 2008 B2
7344509 Hynynen et al. Mar 2008 B2
7384407 Rodriguez et al. Jun 2008 B2
D574961 Kitahara et al. Aug 2008 S
7413556 Zhang et al. Aug 2008 B2
7416535 Kenny Aug 2008 B1
D578543 Ulm et al. Oct 2008 S
7440798 Redding, Jr. Oct 2008 B2
7503895 Rabiner et al. Mar 2009 B2
D592754 Koike et al. May 2009 S
D593117 Lettau May 2009 S
7540852 Nita et al. Jun 2009 B2
7567016 Lu et al. Jul 2009 B2
7604608 Nita et al. Oct 2009 B2
7613516 Cohen et al. Nov 2009 B2
7613664 Riezler et al. Nov 2009 B2
7615030 Murphy et al. Nov 2009 B2
7621902 Nita et al. Nov 2009 B2
7621929 Nita et al. Nov 2009 B2
7648478 Soltani et al. Jan 2010 B2
7715908 Moran et al. May 2010 B2
7717853 Nita May 2010 B2
D617332 Loken et al. Jun 2010 S
7727178 Wilson et al. Jun 2010 B2
7758509 Angelsen et al. Jul 2010 B2
D622841 Bierman Aug 2010 S
7771372 Wilson Aug 2010 B2
7774933 Wilson et al. Aug 2010 B2
7789830 Ishida et al. Sep 2010 B2
7818854 Wilson Oct 2010 B2
7828754 Furuhata et al. Nov 2010 B2
7828762 Wilson et al. Nov 2010 B2
D630727 Petrovic et al. Jan 2011 S
7862576 Gurm Jan 2011 B2
7874985 Kovatchev et al. Jan 2011 B2
7901359 Mandrusov et al. Mar 2011 B2
7914509 Bennett et al. Mar 2011 B2
D637287 Mudd et al. May 2011 S
7976483 Bennett et al. Jul 2011 B2
D643117 Onuma Aug 2011 S
D644649 Fullington et al. Sep 2011 S
8012092 Powers et al. Sep 2011 B2
8062566 Nita et al. Nov 2011 B2
D651212 Bakhreiba et al. Dec 2011 S
8123789 Khanna Feb 2012 B2
8152753 Nita et al. Apr 2012 B2
D658667 Cho et al. May 2012 S
D659151 Loken et al. May 2012 S
8167831 Wilson et al. May 2012 B2
8192363 Soltani et al. Jun 2012 B2
8192391 Soltani et al. Jun 2012 B2
D664257 Patil Jul 2012 S
8226629 Keilman et al. Jul 2012 B1
D664985 Tanghe et al. Aug 2012 S
8298147 Huennekens et al. Oct 2012 B2
D670714 Majeed et al. Nov 2012 S
D670716 Majeed et al. Nov 2012 S
D670725 Mori et al. Nov 2012 S
D671552 Mori et al. Nov 2012 S
D676562 Marzynski Feb 2013 S
8366620 Nita Feb 2013 B2
D685815 Bork et al. Jul 2013 S
D692907 Schuller et al. Nov 2013 S
D694774 Schuller et al. Dec 2013 S
D698925 Marzynski Feb 2014 S
D700343 Liu Feb 2014 S
8690818 Bennett et al. Apr 2014 B2
8696612 Wilson et al. Apr 2014 B2
8740835 Soltani et al. Jun 2014 B2
8762880 Dukhon et al. Jun 2014 B2
D709515 Elston et al. Jul 2014 S
8764700 Zhang et al. Jul 2014 B2
8771186 Kinsley et al. Jul 2014 B2
D711001 Boudier Aug 2014 S
D714339 Hendrickson et al. Sep 2014 S
8819928 Nix et al. Sep 2014 B2
D714948 Vaccarella Oct 2014 S
8852166 Keilman et al. Oct 2014 B1
D725784 Xia et al. Mar 2015 S
D733178 Omiya Jun 2015 S
9044568 Wilcox et al. Jun 2015 B2
9050123 Krause et al. Jun 2015 B2
D733720 Mueller et al. Jul 2015 S
D733738 Omiya Jul 2015 S
D734475 Ross Jul 2015 S
9107590 Hansmann et al. Aug 2015 B2
D741351 Kito et al. Oct 2015 S
D741871 Chung et al. Oct 2015 S
9192566 Soltani et al. Nov 2015 B2
D748124 Jeon Jan 2016 S
D755818 Seo et al. May 2016 S
D758397 Lee Jun 2016 S
D763298 Hoang et al. Aug 2016 S
9415242 Wilson et al. Aug 2016 B2
D767583 Xiong Sep 2016 S
D767584 Xiong Sep 2016 S
D772252 Myers et al. Nov 2016 S
D773491 Ahdrilz et al. Dec 2016 S
D776688 Gamel Jan 2017 S
D779539 Lee et al. Feb 2017 S
9579494 Kersten et al. Feb 2017 B2
D782496 Contreras et al. Mar 2017 S
D783028 Lee et al. Apr 2017 S
D788145 Sullivan et al. May 2017 S
D794662 Genstler et al. Aug 2017 S
D797918 Genstler et al. Sep 2017 S
9849273 Soltani et al. Dec 2017 B2
D812075 Fukagawa Mar 2018 S
9943675 Keilman et al. Apr 2018 B1
D819807 Genstler et al. Jun 2018 S
10080878 Wilson et al. Sep 2018 B2
D831058 Genstler et al. Oct 2018 S
10092742 Genstler et al. Oct 2018 B2
10182833 Soltani et al. Jan 2019 B2
10188410 Soltani et al. Jan 2019 B2
10232196 Soltani et al. Mar 2019 B2
20010000791 Suorsa et al. May 2001 A1
20010003790 Ben-haim et al. Jun 2001 A1
20010007666 Hoffman et al. Jul 2001 A1
20010007861 Newman et al. Jul 2001 A1
20010007940 Tu et al. Jul 2001 A1
20010014775 Koger et al. Aug 2001 A1
20010025190 Weber et al. Sep 2001 A1
20010037106 Shadduck Nov 2001 A1
20010039419 Francischelli et al. Nov 2001 A1
20010041842 Eberle et al. Nov 2001 A1
20010041880 Brisken et al. Nov 2001 A1
20010053384 Greenleaf et al. Dec 2001 A1
20020000763 Jones Jan 2002 A1
20020018472 Rinne et al. Feb 2002 A1
20020019644 Hastings et al. Feb 2002 A1
20020022833 Maguire et al. Feb 2002 A1
20020032394 Brisken et al. Mar 2002 A1
20020040184 Brown et al. Apr 2002 A1
20020041898 Unger et al. Apr 2002 A1
20020045890 Celliers et al. Apr 2002 A1
20020052620 Barbut May 2002 A1
20020055731 Atala et al. May 2002 A1
20020068717 Borrelli Jun 2002 A1
20020068869 Brisken et al. Jun 2002 A1
20020077550 Rabiner et al. Jun 2002 A1
20020082238 Newman et al. Jun 2002 A1
20020087083 Nix et al. Jul 2002 A1
20020099292 Brisken et al. Jul 2002 A1
20020123787 Weiss Sep 2002 A1
20020133081 Ackerman et al. Sep 2002 A1
20020133111 Shadduck Sep 2002 A1
20020150901 Murphy et al. Oct 2002 A1
20020151792 Conston et al. Oct 2002 A1
20020173028 Kapeller-Libermann et al. Nov 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020193708 Thompson et al. Dec 2002 A1
20020198526 Shaolian et al. Dec 2002 A1
20030013986 Saadat Jan 2003 A1
20030023261 Tomaschko et al. Jan 2003 A1
20030028173 Forsberg Feb 2003 A1
20030036705 Hare et al. Feb 2003 A1
20030040501 Newman et al. Feb 2003 A1
20030050662 Don Michael Mar 2003 A1
20030065263 Hare et al. Apr 2003 A1
20030069525 Brisken et al. Apr 2003 A1
20030082649 Weich et al. May 2003 A1
20030083608 Evans et al. May 2003 A1
20030083698 Whitehurst et al. May 2003 A1
20030088187 Saadat et al. May 2003 A1
20030092667 Tachibana et al. May 2003 A1
20030109812 Corl et al. Jun 2003 A1
20030114761 Brown Jun 2003 A1
20030135262 Dretler et al. Jul 2003 A1
20030139774 Epstein et al. Jul 2003 A1
20030153833 Bennett et al. Aug 2003 A1
20030157024 Tachibana et al. Aug 2003 A1
20030163147 Rabiner et al. Aug 2003 A1
20030167023 Bennett et al. Sep 2003 A1
20030187320 Freyman Oct 2003 A1
20030191446 Tachibana et al. Oct 2003 A1
20030199831 Morris et al. Oct 2003 A1
20030216681 Zhang et al. Nov 2003 A1
20030220568 Hansmann et al. Nov 2003 A1
20030229307 Muni et al. Dec 2003 A1
20030233085 Giammarusti Dec 2003 A1
20030236539 Rabiner et al. Dec 2003 A1
20040001809 Brisken et al. Jan 2004 A1
20040010290 Schroeppel et al. Jan 2004 A1
20040015061 Currier et al. Jan 2004 A1
20040015122 Zhang et al. Jan 2004 A1
20040015138 Currier et al. Jan 2004 A1
20040019318 Wilson et al. Jan 2004 A1
20040024347 Wilson Feb 2004 A1
20040024393 Nita et al. Feb 2004 A1
20040039311 Nita et al. Feb 2004 A1
20040039329 Ueberle Feb 2004 A1
20040049148 Rodriguez et al. Mar 2004 A1
20040054351 Deniega et al. Mar 2004 A1
20040059313 Tachibana et al. Mar 2004 A1
20040068189 Wilson et al. Apr 2004 A1
20040077976 Wilson Apr 2004 A1
20040082857 Schonenberger et al. Apr 2004 A1
20040097996 Rabiner et al. May 2004 A1
20040106847 Benderev Jun 2004 A1
20040111195 Vries et al. Jun 2004 A1
20040122354 Semba Jun 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138570 Nita et al. Jul 2004 A1
20040162571 Rabiner et al. Aug 2004 A1
20040171970 Schleuniger et al. Sep 2004 A1
20040171981 Rabiner et al. Sep 2004 A1
20040199228 Wilson Oct 2004 A1
20040210134 Hynynen et al. Oct 2004 A1
20040220514 Cafferata Nov 2004 A1
20040220544 Heruth et al. Nov 2004 A1
20040225318 Eidenschink et al. Nov 2004 A1
20040229830 Tachibana et al. Nov 2004 A1
20040230116 Cowan et al. Nov 2004 A1
20040236350 Lewis et al. Nov 2004 A1
20040243062 Henry Dec 2004 A1
20040254506 Cathignol Dec 2004 A1
20040255957 Cafferata Dec 2004 A1
20040265393 Unger et al. Dec 2004 A1
20050010112 Bennett et al. Jan 2005 A1
20050021063 Hall et al. Jan 2005 A1
20050027247 Garrison et al. Feb 2005 A1
20050038340 Vaezy et al. Feb 2005 A1
20050043629 Rabiner et al. Feb 2005 A1
20050043726 McHale et al. Feb 2005 A1
20050043753 Rabiner et al. Feb 2005 A1
20050054971 Steen et al. Mar 2005 A1
20050065461 Redding Mar 2005 A1
20050090818 Pike et al. Apr 2005 A1
20050096669 Rabiner et al. May 2005 A1
20050113688 Nita et al. May 2005 A1
20050119679 Rabiner et al. Jun 2005 A1
20050124877 Nita et al. Jun 2005 A1
20050137520 Rule et al. Jun 2005 A1
20050177212 Njemanze Aug 2005 A1
20050187513 Rabiner et al. Aug 2005 A1
20050187514 Rabiner et al. Aug 2005 A1
20050192556 Soltani et al. Sep 2005 A1
20050192558 Bernard et al. Sep 2005 A1
20050197619 Rule et al. Sep 2005 A1
20050209578 Christian Evans et al. Sep 2005 A1
20050215942 Abrahamson et al. Sep 2005 A1
20050215946 Hansmann et al. Sep 2005 A1
20050216044 Hong Sep 2005 A1
20050249667 Tuszynski et al. Nov 2005 A1
20050256410 Rabiner et al. Nov 2005 A1
20050277869 Boukhny Dec 2005 A1
20050278633 Kemp Dec 2005 A1
20050288695 Jenson et al. Dec 2005 A1
20060069303 Couvillon Mar 2006 A1
20060078555 Hanley et al. Apr 2006 A1
20060094947 Kovatchev et al. May 2006 A1
20060106308 Hansmann et al. May 2006 A1
20060106375 Werneth et al. May 2006 A1
20060116610 Hare et al. Jun 2006 A1
20060142783 Lewis et al. Jun 2006 A1
20060173387 Hansmann et al. Aug 2006 A1
20060184070 Hansmann et al. Aug 2006 A1
20060241462 Chou et al. Oct 2006 A1
20060241524 Lee et al. Oct 2006 A1
20060264758 Hossack et al. Nov 2006 A1
20060264809 Hansmann et al. Nov 2006 A1
20070005051 Kampa Jan 2007 A1
20070005121 Khanna Jan 2007 A1
20070016040 Nita Jan 2007 A1
20070016041 Nita Jan 2007 A1
20070037119 Pal et al. Feb 2007 A1
20070038100 Nita Feb 2007 A1
20070038158 Nita et al. Feb 2007 A1
20070066900 O'keeffe Mar 2007 A1
20070066978 Schafer et al. Mar 2007 A1
20070083100 Schulz-Stubner Apr 2007 A1
20070083120 Cain et al. Apr 2007 A1
20070106203 Wilson May 2007 A1
20070112268 Zhang et al. May 2007 A1
20070112296 Wilson et al. May 2007 A1
20070123652 Chu et al. May 2007 A1
20070129652 Nita Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070142721 Berner et al. Jun 2007 A1
20070149917 Bennett et al. Jun 2007 A1
20070207194 Grayburn et al. Sep 2007 A1
20070225619 Rabiner et al. Sep 2007 A1
20070239027 Nita Oct 2007 A1
20070249969 Shields Oct 2007 A1
20070255252 Mehta Nov 2007 A1
20070265560 Soltani et al. Nov 2007 A1
20080045865 Kislev Feb 2008 A1
20080065014 Von Oepen et al. Mar 2008 A1
20080103417 Soltani et al. May 2008 A1
20080109029 Gurm May 2008 A1
20080115064 Roach et al. May 2008 A1
20080146918 Magnin et al. Jun 2008 A1
20080154181 Khanna Jun 2008 A1
20080167602 Nita et al. Jul 2008 A1
20080171965 Soltani et al. Jul 2008 A1
20080172067 Nita et al. Jul 2008 A1
20080194954 Unger et al. Aug 2008 A1
20080208109 Soltani et al. Aug 2008 A1
20080221506 Rodriguez et al. Sep 2008 A1
20080228526 Locke et al. Sep 2008 A1
20080235872 Newkirk et al. Oct 2008 A1
20080249501 Yamasaki Oct 2008 A1
20080262350 Unger Oct 2008 A1
20080274097 Tachibana et al. Nov 2008 A1
20080290114 Cabuz et al. Nov 2008 A1
20080306499 Katoh et al. Dec 2008 A1
20080312536 Dala-Krishna Dec 2008 A1
20080315720 Ma et al. Dec 2008 A1
20080319355 Nita Dec 2008 A1
20080319376 Wilcox et al. Dec 2008 A1
20090018472 Soltani et al. Jan 2009 A1
20090073455 Onimura Mar 2009 A1
20090079415 Amada Mar 2009 A1
20090099482 Furuhata et al. Apr 2009 A1
20090105597 Abraham Apr 2009 A1
20090105633 Tachibana et al. Apr 2009 A1
20090112150 Unger et al. Apr 2009 A1
20090187137 Volz et al. Jul 2009 A1
20090209900 Carmeli et al. Aug 2009 A1
20090216246 Nita et al. Aug 2009 A1
20090221902 Myhr Sep 2009 A1
20100010393 Duffy et al. Jan 2010 A1
20100022920 Nita et al. Jan 2010 A1
20100022944 Wilcox Jan 2010 A1
20100023036 Nita et al. Jan 2010 A1
20100023037 Nita et al. Jan 2010 A1
20100049209 Nita et al. Feb 2010 A1
20100063413 Volz Mar 2010 A1
20100063414 Volz Mar 2010 A1
20100081934 Soltani et al. Apr 2010 A1
20100125193 Zadicario May 2010 A1
20100143325 Gurewich Jun 2010 A1
20100160779 Browning et al. Jun 2010 A1
20100160780 Swan et al. Jun 2010 A1
20100196348 Armstrong et al. Aug 2010 A1
20100204582 Lu Aug 2010 A1
20100204642 Wilson et al. Aug 2010 A1
20100210940 Bradley et al. Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100222715 Nita Sep 2010 A1
20100256616 Katoh et al. Oct 2010 A1
20100262215 Gertner Oct 2010 A1
20100280505 Mattiuzzi et al. Nov 2010 A1
20100292685 Katoh et al. Nov 2010 A1
20100317952 Budiman et al. Dec 2010 A1
20100331645 Simpson et al. Dec 2010 A1
20100332142 Shadforth et al. Dec 2010 A1
20110004105 Soltani et al. Jan 2011 A1
20110009720 Kunjan et al. Jan 2011 A1
20110009739 Phillips et al. Jan 2011 A1
20110034791 Moerman Feb 2011 A1
20110112476 Kauphusman et al. May 2011 A1
20110160621 Nita Jun 2011 A1
20110200578 Hanley et al. Aug 2011 A1
20110201974 Soltani et al. Aug 2011 A1
20110264031 Soltani et al. Oct 2011 A1
20110288449 Schenkengel Nov 2011 A1
20110300078 Borden et al. Dec 2011 A1
20110301506 Volz Dec 2011 A1
20110313328 Nita Dec 2011 A1
20110319927 Nita Dec 2011 A1
20120016272 Nita et al. Jan 2012 A1
20120041307 Patel et al. Feb 2012 A1
20120059285 Soltani et al. Mar 2012 A1
20120069285 Koma et al. Mar 2012 A1
20120078140 Nita Mar 2012 A1
20120089082 Zhang et al. Apr 2012 A1
20120095389 Bennett et al. Apr 2012 A1
20120123273 Okuno et al. May 2012 A1
20120172795 Sandhu et al. Jul 2012 A1
20120172858 Harrison et al. Jul 2012 A1
20120179073 Nita Jul 2012 A1
20120197277 Stinis Aug 2012 A1
20120203201 Ginsburg et al. Aug 2012 A1
20120209116 Hossack et al. Aug 2012 A1
20120253237 Wilson et al. Oct 2012 A1
20120265123 Khanna Oct 2012 A1
20120271203 Soltani et al. Oct 2012 A1
20120271223 Khanna Oct 2012 A1
20120289889 Genstler et al. Nov 2012 A1
20120330141 Brown et al. Dec 2012 A1
20120330144 Brown et al. Dec 2012 A1
20120330196 Nita Dec 2012 A1
20130073306 Shlain et al. Mar 2013 A1
20130204166 Villanueva et al. Aug 2013 A1
20130211316 Wilcox et al. Aug 2013 A1
20130216593 Borden et al. Aug 2013 A1
20130289398 Borden et al. Oct 2013 A1
20130331738 Borrelli Dec 2013 A1
20140046313 Pederson Feb 2014 A1
20140128734 Genstler et al. May 2014 A1
20140155814 Bennett et al. Jun 2014 A1
20140210631 Zavis Jul 2014 A1
20140226901 Spracklen et al. Aug 2014 A1
20140236005 Chen et al. Aug 2014 A1
20140236118 Unser et al. Aug 2014 A1
20140249453 Wilson et al. Sep 2014 A1
20140276367 Kersten et al. Sep 2014 A1
20140316329 Soltani et al. Oct 2014 A1
20140343483 Zhang et al. Nov 2014 A1
20150095807 Duncker et al. Apr 2015 A1
20150173673 Toth Jun 2015 A1
20150178044 Ehlen et al. Jun 2015 A1
20160030725 Kersten et al. Feb 2016 A1
20160082243 Genstler et al. Mar 2016 A1
20160262777 Stigall Sep 2016 A1
20160361528 Kanz et al. Dec 2016 A1
20170007815 Wilson et al. Jan 2017 A1
20170182302 Kersten et al. Jun 2017 A1
20180206867 Allen Jul 2018 A1
20190054274 King Feb 2019 A1
20190091458 Wilson et al. Mar 2019 A1
20190099591 Genstler et al. Apr 2019 A1
20190216477 Soltani et al. Jul 2019 A1
20190223894 Soltani et al. Jul 2019 A1
20190223895 Volz Jul 2019 A1
20190269944 Soltani et al. Sep 2019 A1
Foreign Referenced Citations (178)
Number Date Country
634470 Feb 1993 AU
1083040 Aug 1980 CA
1193267 Sep 1998 CN
1309331 Aug 2001 CN
1358988 Jul 2002 CN
1720874 Jan 2006 CN
301040544 Oct 2009 CN
301877182 Apr 2012 CN
102548603 Jul 2012 CN
3919592 Feb 1990 DE
4005743 Aug 1991 DE
108658 May 1984 EP
122624 Oct 1984 EP
189329 Jul 1986 EP
224934 Jun 1987 EP
278074 Aug 1988 EP
327490 Aug 1989 EP
0338971 Oct 1989 EP
495531 Jul 1992 EP
504881 Sep 1992 EP
520486 Dec 1992 EP
0529675 Mar 1993 EP
0586875 Mar 1994 EP
617913 Oct 1994 EP
625360 Nov 1994 EP
629382 Dec 1994 EP
634189 Jan 1995 EP
668052 Aug 1995 EP
670147 Sep 1995 EP
732106 Sep 1996 EP
744189 Nov 1996 EP
0746245 Dec 1996 EP
788774 Aug 1997 EP
1090658 Apr 2001 EP
1103281 May 2001 EP
1145731 Oct 2001 EP
1252885 Oct 2002 EP
1453425 Sep 2004 EP
1463454 Oct 2004 EP
1595576 Nov 2005 EP
1647232 Apr 2006 EP
2015846 Jan 2009 EP
2170181 Apr 2010 EP
2231024 Sep 2010 EP
2448636 May 2012 EP
2494932 Sep 2012 EP
2608730 Jul 2013 EP
2727544 May 2014 EP
1577551 Oct 1980 GB
5211591 Sep 1977 JP
5856869 Apr 1983 JP
5963783 Apr 1984 JP
59108378 Jun 1984 JP
61244079 Oct 1986 JP
02180275 Jul 1990 JP
03063041 Mar 1991 JP
03170172 Jul 1991 JP
03176077 Jul 1991 JP
03221421 Sep 1991 JP
06233779 Aug 1994 JP
08243168 Sep 1996 JP
2001228601 Aug 2001 JP
2001340336 Dec 2001 JP
2002501402 Jan 2002 JP
2002136537 May 2002 JP
2002519095 Jul 2002 JP
2003509152 Mar 2003 JP
2005512630 May 2005 JP
2006055649 Mar 2006 JP
2006510449 Mar 2006 JP
2007520281 Jul 2007 JP
2009508630 Mar 2009 JP
D1456367 Nov 2012 JP
614788 Jul 1978 SU
654254 Mar 1979 SU
931191 May 1982 SU
1003853 Mar 1983 SU
1103863 Jul 1984 SU
1146059 Mar 1985 SU
1648497 May 1991 SU
80001365 Jul 1980 WO
08002365 Nov 1980 WO
89004142 May 1989 WO
89005159 Jun 1989 WO
89005160 Jun 1989 WO
89006978 Aug 1989 WO
90001300 Feb 1990 WO
90001971 Mar 1990 WO
91003264 Mar 1991 WO
91009629 Jul 1991 WO
91012772 Sep 1991 WO
91019529 Dec 1991 WO
92000113 Jan 1992 WO
92007622 May 1992 WO
93008738 May 1993 WO
94005361 Mar 1994 WO
94005368 Mar 1994 WO
94017734 Aug 1994 WO
94028873 Dec 1994 WO
95001751 Jan 1995 WO
95005866 Mar 1995 WO
95009572 Apr 1995 WO
95010233 Apr 1995 WO
95015118 Jun 1995 WO
9526777 Oct 1995 WO
9527443 Oct 1995 WO
9604955 Feb 1996 WO
9607432 Mar 1996 WO
9615815 May 1996 WO
9627341 Sep 1996 WO
9629935 Oct 1996 WO
9635469 Nov 1996 WO
9636286 Nov 1996 WO
9639079 Dec 1996 WO
9707735 Mar 1997 WO
9719644 Jun 1997 WO
9719645 Jun 1997 WO
9721462 Jun 1997 WO
9727808 Aug 1997 WO
9740679 Nov 1997 WO
9809571 Mar 1998 WO
9811826 Mar 1998 WO
9818391 May 1998 WO
9829055 Jul 1998 WO
9840016 Sep 1998 WO
9848711 Nov 1998 WO
9856462 Dec 1998 WO
9858699 Dec 1998 WO
9916360 Apr 1999 WO
9925385 May 1999 WO
9932184 Jul 1999 WO
9933500 Jul 1999 WO
9933550 Jul 1999 WO
9934858 Jul 1999 WO
9939647 Aug 1999 WO
9939738 Aug 1999 WO
9942039 Aug 1999 WO
99044512 Sep 1999 WO
00000095 Jan 2000 WO
00012004 Mar 2000 WO
00018468 Apr 2000 WO
00038580 Jul 2000 WO
00069341 Nov 2000 WO
01013357 Feb 2001 WO
0121081 Mar 2001 WO
01054754 Aug 2001 WO
01074255 Oct 2001 WO
01087174 Nov 2001 WO
01095788 Dec 2001 WO
0213678 Feb 2002 WO
0215803 Feb 2002 WO
0215804 Feb 2002 WO
03007649 Jan 2003 WO
03051208 Jun 2003 WO
03099382 Dec 2003 WO
2004058045 Jul 2004 WO
2005027756 Mar 2005 WO
2005072391 Aug 2005 WO
2005072409 Aug 2005 WO
2005079415 Sep 2005 WO
2005084552 Sep 2005 WO
2005084553 Sep 2005 WO
2006110773 Oct 2006 WO
2007127176 Nov 2007 WO
2008052186 May 2008 WO
2008086372 Jul 2008 WO
2009002881 Dec 2008 WO
2009018472 Feb 2009 WO
2009079415 Jun 2009 WO
2010003130 Jan 2010 WO
2011003031 Jan 2011 WO
2011011539 Jan 2011 WO
2011056311 May 2011 WO
2012027722 Mar 2012 WO
2014159274 Oct 2014 WO
2015074036 May 2015 WO
WO-2015074036 May 2015 WO
2016201136 Dec 2016 WO
Non-Patent Literature Citations (77)
Entry
Abbas, “Development of a Low Cost Shock Pressure Sensor”, Thesis, Ohio University, College of Engineering and Technology, Mar. 1988, pp. 149.
Akdemir et al., “Treatment of Severe Intraventricular Hemorrhage by Intraventricular Infusion of Urokinase”, Neurosurgical Review, 1995, vol. 18, No. 2, pp. 95-100.
Akhtar, “Anti-HIV Therapy With Antisense Oligonucleotides and Ribozymes: Realistic Approaches or Expensive Myths?” Antimicrob Chemother, 1996, vol. 2, pp. 159-165.
Anderson, “Human Gene Therapy,” Nature, 1998, vol. 392, pp. 25-30.
Butler, “Production of Microbubbles for Use as Echo Contrast Agents”, Journal of Clinical Ultrasound, Jun. 1986, vol. 14, pp. 408-412.
Bleeker et al., “On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion”, Journal of Ultrasound in Medicine, Aug. 1990, vol. 9, No. 8, pp. 461-471.
Branch, Andrea D., “A Good Antisense Molecule is Hard to Find”, Trends in Biochem Science 23, Feb. 1998, pp. 45-50.
Bao et al. “Transfection of a Reporter Plasmid into Cultured Cells by Sonoporation In Vitro,” Ultrasound in Medicine and Biology Journal, 1997, vol. 23, No. 6, pp. 953-959.
Broderick et al., “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: a Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association”, Stroke, Journal of the American Heart Association, 1999, pp. 905-915.
Tachibana et al., “Liver tissue damage by ultrasound in combination with the photosensitizing drug, Photofrin II,” Cancer Letters, vol. 78, (1-3), 1994, pp. 177-181.
Tachibana et al., “Enhancement of Cell killing of HL-60 cells by ultrasound in the presence of the photosensitizing drug Photofrin II,” Cancer Letters, vol. 72, 1993, pp. 195-199.
Chamsuddin et al., “Catheter-directed Thrombolysis with the Endowave System in the Treatment of Acute Massive Pulmonary Embolism: a Retrospective Multicenter Case Series,” Journal of Vascular and Interventional Radiology, Mar. 2008, vol. 19, No. 3, pp. 372-376.
U.S. Appl. No. 10/291,890, filed Nov. 7, 2002.
Crooke, Basic Principles of Antisense Therapeutics, Springer-Verlag, Eds, New York, 1998, pp. 1 and 4.
Deinsberger et al., “Stereotactic Aspiration and Fibrinolysis of Spontaneous Supratentorial Intracerebral Hematomas versus Conservative Treatment: a Matched-Pair Study”, Zentralblatt für Neurochirurgie, Dec. 18, 2003, vol. 64, No. 4, pp. 145-150.
“EkoSonic® MACH4e”, EKOS Advertisement, Venous Times, Issue 6, dated Jan. 2010, p. 3.
Fechmeier et al. “Transfection of Mammalian Cells with Plasid DNA by Scrape Loading and Sonication Loading,” Proc. Natl. Acad. Sci. USA, Dec. 1987, vol. 84, pp. 8463-8467.
Feinstein et al., “Two-dimensional Contrast Echocardiography. I. In Vitro Development and Quantitative Analysis of Echo Contrast Agents”, Journal of the American College of Cardiology, Jan. 1984, vol. 3, No. 1, pp. 14-20.
Feldman et al. “Optimal Techniques for Arterial Gene Transfer,” Cardiovascular Research, 1997, vol. 35, pp. 391-404.
Findlay et al., “Lysis of Intraventricular Hematoma with Tissue Plasminogen Activator”, Journal of Neurosurgery, 1991, vol. 74, pp. 803-807.
Frémont et al., “Prognostic Value of Echocardiographic Right/Left Ventricular End-Diastolic Diameter Ratio in Patients With Acute Pulmonary Embolism: Results From a Monocenter Registry of 1,416 Patients”, Chest, Feb. 2008, vol. 133, No. 2, pp. 358-362.
Gilles et al., “Cavitation Generated by Amplitude Modulated HIFU: Investigations on the Inertial Cavitation Threshold,” AIP Conference Proceedings: 6th Int. Symposium on Theraputic Ultrasound, May 21, 2007, vol. 911, pp. 171-177.
Greenleaf, William J. et al.; Arlifical Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. vol. 24, No. 4 pp. 587-595, 1998.
Ho et al. “Antisense Oigonucleoties and Therapeutics for Malignant Diseases,” Seminars in Drug Discovery 24, 1997, vol. 2, pp. 187-202.
Holland et al., “Thresholds for Transient Cavitation Produced by Pulsed Ultrasound in a Controlled Nuclei Environment”, The Journal of the Acoustical Society of America, Nov. 1990, vol. 88, No. 5, pp. 2059-2069.
Hynynen et al.; “Small Cylindrical Ultrasound Sources for Induction of Hyperthermia via Body Cavities or Interstitial Implants”, Arizona Cancer Center and Department of Radiation Oncology, University of Arizona Health Sciences Center; vol. 9, No. 2, 1993, pp. 263-274.
Jaff et al., “Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: a Scientific Statement From the American Heart Association”, Challenging Forms of Venous Thromboembolic Disease, Circulation, 2011, vol. 123, pp. 1788-1830.
Japanese Journal of Cancer Research, vol. 81, No. 3, Mar. 1990, pp. 304-308.
Jeffers, R.J. et al.; Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms, 1993.
Jeffers, Russel et al.; Dimethylformamide as an Enhancer of Cavitation-Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
Keller et al., “Automated Production and Analysis of Echo Contrast Agents”, Journal of Ultrasound in Medicine, Sep. 1986, vol. 5, pp. 493-498.
Kim et al. “Ultra-sound Mediated Transfection of Mammalian Cells,” Human Gene Therapy, Jul. 10, 1996, vol. 7, pp. 1339-1346.
Kim, Timothy F., “Microbubbles Show Promise for Enhancing Ultrasound Signal, Image, Other Applications”, The Journal of the American Medical Association, Mar. 1989, vol. 281, No. 11, p. 1542.
Kotnis et al. “Optimisation of Gene Transfer into Vascular Endothelial Cells Using Electroporation,” Eur J. Vasc Surg, 1995, vol. 9, pp. 71-79.
Kucher et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism”, Ultrasound Thrombolysis for Pulmonary Embolism, Circulation, 2014, vol. 129, pp. 479-486.
Lang et al., “Contrast Ultrasonography of the Kidney: a New Method for Evaluation of Renal Perfusion in Vivo”, Circulation, 1987, vol. 75, No. 1, pp. 229-234.
Lee et al.; “Arrays of Multielement Ultrasound Applicators for Interstitial Hyperthermia”; IEEE Transactions on biomedical Engineering; vol. 46, No. 7, Jul. 1999, pp. 880-890.
Leong et al., “Polyanhydrides for Controlled Release of Bioactive Agents”, Biomaterials, Sep. 1986, vol. 7, pp. 364-371.
Lin et al., “Comparison of Percutaneous Ultrasound-Accelerated Thrombolysis versus Catheter-Directed Thrombolysis in Patients with Acute Massive Pulmonary Embolism,” Vascular, 2009, vol. 17, No. 3, pp. S137-S147.
Matsumoto et al., “CT-Guided Stereotaxic Evacuation of Hypertensive Intracerebral Hematomas”, Journal of Neurosurgery, Sep. 1984, vol. 61, No. 3, pp. 440-448.
Mayfrank et al., “Fibrinolytic Treatment of Intraventricular Haemorrhage Preceding Surgical Repair of Ruptured Aneurysms and Arteriovenous Malformations”, British Journal of Neurosurgery, 1999, vol. 13, No. 2, pp. 128-131.
Maywald et al., “Experience With Atraumatic Vascular Diagnosis With the Aid of the Ultrasonic Doppler Technique”, Electromedica, 1976, vol. 2 pp. 43-48.
Meltzer et al., “The Source of Ultrasound Contrast Effect”, Journal of Clinical Ultrasound, Apr. 1980, vol. 8, No. 2, pp. 121-127.
Meyer et al., “Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism”, N. Engl, J. Med., 2014, vol. 340, pp. 1402-1411.
Miller, Douglas L. et al.; Sonoporation of Cultured Cells in the Rotation Tube Exposure System, vol. 25, No. 1, 1999.
Mohadjer et al., “CT-Guided Stereotactic Fibrinolysis of Spontaneous and Hypertensive Cerebellar Hemorrhage: Long-Term Results”, Journal of Neurosurgery, Aug. 1990, vol. 73, No. 2, pp. 217-222.
Niizuma et al., “CT-Guided Stereotactic Aspiration of Intracerebral Hematoma—Result of a Hematoma-Lysis Method Using Urokinase”, Applied Neurophysiology, Proceedings of the Ninth Meeting of the World Society, Jul. 4-7, 1985, pp. 4.
Niizuma et al., “Results of Stereotactic Aspiration in 175 Cases of Putaminal Hemorrhage”, Neurosurgery, Jun. 1989, vol. 24, No. 6, pp. 814-819.
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995, pp. 1-38.
Pang et al., “Lysis of Intraventricular Blood Clot with Urokinase in a Canine Model: Part 1”, Neurosurgery, 1986, vol. 19, No. 4, pp. 540-546.
“Photophoresis Apparatus in Treatment of a Cutis T Cell Lymphadenoma,” Science (Japan Edition), Oct. 1988, pp. 65-73.
Porter et al. “Interaction of Diagnostic Ultrasound with Synthetic Olionucleotide-Labeled Perfluorcarbon-Exposed Sonicated Dextrose Albumin Microbubbles,” J Ultrasound Med, 15:557-584, 1996.
Porter et al., Thrombolytic Enhancement With Perfluorocarborn-Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.
Prat et al., “In Vivo Effects of Cavitation Alone or in Combination with Chemotherapy in a Peritoneal Carcinomatosis in the Rat,” 1993, vol. 68, pp. 13-17.
Price et al.; Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created by Targeted Microbubble Destruction With Ultrasound, Sep. 29, 1998.
Rohde et al., “Intraventricular Recombinant Tissue Plasminogen Activator for Lysis of Intraventricular Haemorrhage”, Journal of Neurology and Neurosurgery Psychiatry, 1995, vol. 58, pp. 447-451.
Romano et al., Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutice Applications, (Stem Cells 18: 19-39, 2000).
Rosenschein et al., “Experimental Ultrasonic Angioplasty: Disruption of Atherosclerotic Plaques and Thrombi in Vitro and Arterial Recanalization in Vivo,” Journal of the American College of Cardiology, Mar. 1, 1990, vol. 15, No. 3, pp. 711-717.
Saletes et al., “Acoustic Cavitation Generated by BiFrequency Excitation” University De Lyon, Dec. 2009.
Saletes et al., “Cavitation par Excitation Acoustique Bifréquentielle: Application á la Thrombolyse Ultrsonore,” N' d'ordre 311, Universite de Lyon, Dec. 7, 2009, pp. 110.
Saletes et al., “Efficacité d'une Excitation Bifréquentielle en Thrombolyse Purement Ultrsonore,” 10éme Congrés Français d'Acoustique, Universite de Lyon, Apr. 12-16, 2010.
Schäfer et al., “Influence of Ultrasound Operating Parameters on Ultrasound-Induced Thrombolysis In Vitro,” Ultrasound in Medicine and Biology, vol. 31, No. 6, Mar. 2005, pp. 841-847.
Schaller et al., “Stereotactic Puncture and Lysis of Spontaneous Intracerebral Hemorrhage Using Recombinant Tissue-Plasminogen Activator”, Neurosurgery, Feb. 1995, vol. 36, No. 2, pp. 328-335.
Somia et al., “Gene Therapy: Trials and Tribulations,” Nature Reviews Genetics, 2000, vol. 1, pp. 91-99.
Tachibana K.; Albumin Microbubble Echo-Contrast Materials as an Enhancer for Ultrasound Accelerated Thrombolysis, Sep. 1, 1995.
Tachibana, “Enhancement of Fibrinolysis with Ultrasound Energy”, JVIR, vol. 3, No. 2, May 1992, pp. 299-303.
Teernstra et al., “Stereotactic Treatment of Intracerebral Hematoma by Means of a Plasminogen Activator. A Multicenter Randomized Controlled Trial (SICHPA”, Stroke, Journal of the American Heart Association, Mar. 20, 2003, pp. 968-974.
Tsetis et al., “Potential Benefits From Heating the High-Dose Rtpa Boluses Used in Catheter-Directed Thrombolysis for Acute/Subacute Lower Limb Ischemia”, Journal of Endovascular Therapy, 2003, vol. 10, pp. 739-744.
Tsurumi, et al. “Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion,” Circulation, 1996; 94: 3281-3290.
Unger et al., “Ultrasound Enhances Gene Expression of Liposomal Transfection,” Investigative Radiology, vol. 32, No. 12, pp. 723-727, 1997.
Unger et al., “Acoustically Active Liposheres Containing Paclitaxel,” vol. 11, No. 12, 1992.
Vandenburg et al., “Myocardial Risk Area and Peak Gray Level Measurement by Contrast Echocardiography: Effect of Microbubble Size and Concentration, Injection Rate, and Coronary Vasodilation,” American Heart Journal, Apr. 1988, vol. 115, No. 4, pp. 733-739.
Verma et al., “Gene Therapy—Promises, Problems and Prospects,” Nature, 1997, vol. 389, pp. 239-242.
Wheatly et al., “Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles,” Biomaterials, Nov. 1990, vol. 11, No. 19, pp. 713-717.
Wu, Yunqiu et al., “Binding as Lysing of Blood Clots Using MRX-408,” Investigative Radiology, Dec. 1998, vol. 33, No. 12, pp. 880-885.
Wyber et al., “The Use of Sonication for the Efficient Delivery of Plasmid DNA into Cells,” Pharmaceutical Research, vol. 14, No. 6, pp. 750-756.
Yumita et al., “Synergistic Effect of Ultrasound and Hematoporphyrin on Sarcoma 180”, Japanese Journal of Cancer Research, vol. 81, No. 3, Mar. 1990, pp. 304-308.
Related Publications (1)
Number Date Country
20200109994 A1 Apr 2020 US
Provisional Applications (1)
Number Date Country
62173863 Jun 2015 US
Continuations (1)
Number Date Country
Parent 15178398 Jun 2016 US
Child 16702520 US